

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/14319 A2

(51) International Patent Classification⁷: **C07D 487/00**

(21) International Application Number: **PCT/US01/24390**

(22) International Filing Date: **2 August 2001 (02.08.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/224,724 11 August 2000 (11.08.2000) US

(71) Applicant: **BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.** [US/US]; 900 Ridgebury Road, P. O. Box 368, Ridgefield, CT 06877-0368 (US).

Tina, Marie; 114 Taylor Road, New Milford, CT 06776 (US). **MOSS, Neil**; 199 Barlow Mountain Road, Ridgefield, CT 06877 (US). **PROKOPOWICZ III, Anthony, S.**; 20 Sun Up Road, Stormville, NY 12582 (US). **SELLIAH, Robert, D.**; 250 Kennedy Drive, #407, Malden, MA 02148 (US). **TAKAHASHI, Hidenori**; 68 Ehmer Drive, LaGrangeville, NY 12540 (US).

(74) Agents: **RAYMOND, Robert, P. et al.**; Boehringer Ingelheim Corporation, 900 Ridgebury Road, P. O. Box 368, Ridgefield, CT 06877-0368 (US).

(81) Designated States (*national*): **CA, JP, MX.**


(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(72) Inventors: **SNOW, Roger, John**; 29 East Gate Road, Danbury, CT 06811 (US). **GAO, Donghong, A.**; 52 Harrison's Trail, Hopewell Junction, NY 12533 (US). **GOLDBERG, Daniel, R.**; 31 Highland Avenue, Redding, CT 06896 (US). **HAMMACH, Abdelhakim**; 8 Rolf's Drive, Danbury, CT 06810 (US). **KUZMICH, Daniel**; 4 Driftway Road, Unit C1, Danbury, CT 06811 (US). **MORWICK,**

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/14319 A2

(54) Title: **HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES**

(57) Abstract: Disclosed are novel compounds of formula (I) (see formula I as described in specification) wherein Ar₁, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.


HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES

5

Field of the Invention

This invention relates to substituted compounds of formula (I):

10



(I)

wherein Ar₁, X, Y, P, Q and Het are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases, processes for preparing these compounds and intermediate useful in these processes.

25 Tyrosine kinases play an essential role in the regulation of cell signaling and cell proliferation by phosphorylating tyrosine residues of peptides and proteins. Inappropriate

Background of the Invention

activation of tyrosine kinases is known to be involved in a variety of disease states, including immunologic and oncologic disorders.

It has been well established that T cells play an important role in regulating the immune response (F. Powrie and R.L. Coffman, *Immunol. Today*, 1993, 14, 270). Activation of T cells is often the initiating event in many inflammatory and autoimmune diseases. In addition to their role in immune surveillance, T cells can become autoreactive by recognizing self-antigens and thereby cause autoimmune disease such as rheumatoid arthritis and inflammatory bowel disease.

10

The T cell receptor (TCR) is the antigen-specific component of the T cell and is activated when the receptor is engaged with foreign or self-antigenic peptides. When the TCR is activated a series of enzyme-mediated signal transduction cascades is initiated which results in the production of pro-inflammatory cytokines such as interleukin-2 (IL-2). The release of IL-2 is critically important since this lymphokine is required for T-lymphocyte proliferation, differentiation, and effector function. Clinical studies have shown that interference with IL-2 activity effectively suppresses immune response *in vivo* (T.A. Waldmann, *Immunol. Today*, 1993, 14, 270). Accordingly, agents which inhibit T-lymphocyte activation and subsequent IL-2 production, or block the activity of IL-2 are therapeutically useful for selectively suppressing immune response in a patient in need of such immunosuppression.

The eight members of the src family of tyrosine kinases are src, lck, fyn, lyn, hck, fgr, blk and yes (J.B. Bolen, J.S. Brugge, *Ann. Rev. Immunol.*, 1997, 15, 371). These can be divided into 2 groups based on their pattern of tissue expression. Src, fyn and yes have a broad distribution while expression of lck, lyn, hck, fgr, and blk is largely limited to hemopoietic cells. The therapeutic effects of inhibiting kinases of the src family can be ascertained by linking functional defects seen in gene disruption studies in mice. Src(-/-) mice had severe abnormalities in bone remodeling. Inhibition of src may therefore be useful in treating osteoporosis. Lck(-/-) mice display a complete lack of CD4+ cells are unable to mount antigen-dependent immune responses.

30

A kinase of particular interest is p56lck, which is only expressed in T-cells. Within the TCR signal transduction cascade the tyrosine kinase p56lck is a required element to initiate the activation response from the TCR intracellular domains to other signaling proteins. For example, T cells which lack the p56lck protein are unable to signal through the T cell receptor (D.B. Straus and A. Weiss, *Cell*, 1992, 70, 585). Transfection of p56lck back into these cell lines restores TCR responsiveness. Also, it has been shown in mice that inactivation of the p56lck gene leads to lack of proper thymocyte development (T.J. Molina et al., *Nature*, 1992, 357, 161).

10

The conclusion drawn from these studies is that p56lck plays a crucial role in T cell maturation and antigen-induced T-cell activation. Therefore, an agent blocking p56lck would effectively block T cell function, act as an immunosuppressive agent and have potential utility in autoimmune diseases, for example rheumatoid arthritis, multiple sclerosis, lupus, transplant rejection and allergic diseases (J.H. Hanke et al., *Inflamm. Res.*, 1995, 44, 357).

Inhibitors of other members of the src family of non-receptor tyrosine kinases are also useful for treating various disease states. Src is present in osteoclasts, and is important in bone remodeling. For example, inactivation of p60src diminishes bone resorption by osteoclasts (P. Soriano et al., *Cell* 1991, 64, 693, B.F. Boyce et al. *J. Clin. Invest* 1992, 90, 1622), it is therefore possible that inhibitors of the kinase activity of p60src are useful in the treatment of osteoporosis, Paget's disease and inflammation of bones and joints.

25

Src kinases have been found to be activated in tumors, including breast and colon cancers, melanoma and sarcoma. For example, a number of primary tumors and tumor cell lines from patients with breast cancer, colon cancer, melanoma and sarcoma have been shown to have elevated src kinase activity, and activating src mutations are seen in some advanced colon cancers. Inhibitors of src kinase had significant antiproliferative activity against cancer cell lines (M.M. Moasser et al., *Cancer Res.*, 1999, 59, 6145) and inhibited the

30

transformation of cells to an oncogenic phenotype (R. Karni et al., *Oncogene*, 1999, 18, 4654) suggesting that src kinase inhibitors may be useful anti-cancer agents.

Src inhibitors have also been reported to be effective in an animal model of cerebral ischemia (R. Paul et al. *Nature Medicine* 2001, 7, 222), suggesting that src kinase inhibitors may thus be useful in treating conditions involving cerebral ischemia. For example, src kinase inhibitors may be useful in reducing brain damage following stroke.

In addition, src family kinases participate in signal transduction in several cell types. For example, fyn, like lck, is involved in T-cell activation. Hck and fgr are involved in Fc gamma receptor mediated oxidative burst of neutrophils. Src and lyn are believed to be important in Fc epsilon induced degranulation of mast cells, and so may play a role in asthma and other allergic diseases. The kinase lyn is known to be involved in the cellular response to DNA damage induced by UV light (T. Hiwasa, *FEBS Lett.* 1999, 444, 173) or ionizing radiation (S. Kumar, *J. Biol Chem*, 1998, 273, 25654). Inhibitors of lyn kinase may thus be useful as potentiators in radiation therapy.

Platelet derived growth factor is a potent mitogen for smooth muscle cells. Its receptor (PDGFR) is a member of the receptor tyrosine kinase family (L. Claesson-Welsh, *J. Biol Chem*, 1994, 269, 32023). PDGF is involved in atherosclerosis and restenosis (K.E. Bornfeldt, *Trends Cardiovasc. Med.*, 1996, 6, 143). In addition, receptor tyrosine kinases including PDGFR kinase have been implicated as contributing factors in cancer (A. Levitzki and A. Gazit, *Science*, 1995, 267, 1782) including ovarian (M.B. Dabrow et al., *Gynecologic Oncology*, 1998, 71, 29) and prostate (S.M. Sintich et al., *Endocrinology*, 1999, 140, 3411) cancers and glioblastoma (B.J. Silver, *BioFactors*, 1992 3, 217). Inhibitors of PDGFR kinase are thus useful in the treatment of fibrotic diseases, restenosis and PDGF-dependent tumors.

Reports have appeared in the literature of agents that inhibit the kinase activity of p56lck kinase and thus inhibit T cell activation. These include the natural product lavendustin A, and analogs (M.S. Smyth, *J. Med. Chem.*, 1993, 36, 3010), the natural product

damnacanthal (C.R. Faltynek et al., *Biochemistry*, 1995, 34, 12404), and a 1-methoxy agroclavine isolated from a fungal extract (R. Padmanabha et al. *Bioorganic and Med. Chem. Letters*, 1998, 8, 569). Other inhibitors reported include WIN 61651 (*J. Enzyme Inhibition*, 1995, 9, 111) pyrazolopyrimidines PP1 and PP2 (Hanke et al. *J. Biol Chem*, 5 1996, 271, 695) and indanone and indandione derivatives (J.L. Bullington et al., *Bioorganic and Med. Chem. Letters*, 1998, 8, 2489).

A.P. Spader et al. (WO 98/54157, 1998) describe quinoline and quinoxaline compounds that inhibit p56lck and PDGFR kinase. Fused polycyclic 2-aminopyrimidine derivatives 10 that inhibit p56lck are reported by J.M. Davis et al. (WO 98/28281, 1998). J. Das et al. claim a series of benzothiazole amides as inhibitors of lck and other src family kinases (WO 99/24035, 1999). Inhibitors of PDGFR kinase and src-family kinases were reviewed by H.D.H. Showalter, A.J. Kraker, *Pharmacol. Ther.*, 1997, 76, 55. Several patents on inhibitors of lck are reviewed in P.M. Traxler, *Exp. Opin. Ther. Patents*, 1997, 7, 571, and 15 P.M. Traxler, *Exp. Opin. Ther. Patents*, 1998, 8, 1599.

EP 322 746 A1 discloses heterocyclic lactam derivatives described as being useful as cardiotonic agents, antihypertensive agents and vasodilators.

20 Examples of tricyclic systems similar to formula (I) above are known, but not having the 2-amino substituents on the benzimidazole ring. See S. W. Schneller et al., *J. Med. Chem.*, 1989, 32, 2247. Examples of tricyclic systems similar to formula (I) with a carbamate at the 2-position have been reported in S. Kumar et al., *Indian J. Chem.* 1981, 20B, 1068 and S. Agarwal et al., *Z. Naturforsch. C*, 1993, 48, 829.

25

The compounds of the present invention represent a novel structural class, which is distinct from previously reported tyrosine kinase inhibitors.

30

Brief Summary of the Invention

The work cited above supports the principle that inhibition of the kinases mentioned above will be beneficial in the treatment of various disease states.

5

It is therefore an object of the invention to provide novel compounds which inhibit PDGFR kinase and the src-family kinases including lck, src, fyn, lyn, hck, fgr, blk and yes.

10 It is a further object of the invention to provide methods for treating diseases and pathological conditions mediated by src-family tyrosine kinases and PDGFR kinase such as autoimmune diseases, transplant rejection, psoriasis, osteoporosis, Paget's disease, cancer, including src-dependent tumors and PDGF-dependent tumors, cerebral ischemic conditions, atherosclerosis, restenosis and allergic diseases, using the novel compounds of the invention.

15

It is yet a further object of the invention to provide processes of preparation of the above-mentioned novel compounds and pharmaceutical compositions comprising the same.


Detailed Description of the Invention

20

The src-family tyrosine kinases and PDGFR kinase discussed above exhibit some homology in their amino acid structure. It is contemplated that due to structural differences between individual src-family kinases and PDGFR kinase, different compounds of the invention may have different inhibitory potencies against individual tyrosine kinases. Thus
25 some of compounds of the invention may also be expected to be most effective in treating diseases mediated by tyrosine kinases that they inhibit most potently. Particular compounds disclosed herein have been shown to be active inhibitors of p56lck kinase, p60src kinase and PDGFR kinase. See the section entitled "Assessment of Biological Properties" disclosed herein.

30

In its broadest generic aspect, the invention provides novel compounds of the formula (I) below:



(I)

wherein:

Ar_1 is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle; wherein said carbocycle, heteroaryl or heterocycle is optionally substituted by one or more R_1 , R_2 and R_3 ;


X is NH , $N-C_{1-3}alkyl$, $N-cyclopropyl$, S or O ;

Y is NR_{13} ;

R_1 and R_2 are the same or different and are selected from H , halogen, CN , NO_2 , C_{1-10} branched or unbranched saturated or unsaturated alkyl, C_{1-10} branched or unbranched alkoxy, C_{1-10} branched or unbranched acyl, C_{1-10} branched or unbranched acyloxy, C_{1-10} branched or unbranched alkylthio, aminosulfonyl, di- $(C_{1-3})alkylaminosulfonyl$, NR_8R_9 , aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned R_1 and R_2 are optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH , NR_8R_9 , C_{1-6} branched or unbranched alkyl, $C_{3-7}cycloalkyl$, phenyl, naphthyl, heteroaryl, aminocarbonyl and mono- or di- $(C_{1-3})alkylaminocarbonyl$;

R_3 is selected from the group consisting of H, halogen, OH, $(CH_2)_nNR_8R_9$, $(CH_2)_nCO_2R_{10}$, C_{1-3} alkyl optionally substituted with OH, C_{1-3} alkoxy optionally halogenated and C_{1-3} alkylthio;

- 5 Het represents a fused heterocyclic ring having a formula A, B or C:



- R_4 is selected from H, C_{1-6} alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C_{1-3} alkoxy, C_{3-10} -cycloalkyl, or C_{5-8} cycloalkenyl;
- 10 or R_4 is selected from $(CH_2)_mNR_8R_9$, $(CH_2)_mNR_8COR_{10}$, $(CH_2)_nCO_2R_{10}$, $(CH_2)_nCONR_8R_9$, phenyl, heteroaryl or heterocycle, each phenyl, heteroaryl or heterocycle being optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, $(CH_2)_mNR_8R_9$, OH, SO_3H or halogen;
- 15 R_5 is selected from H, C_{1-10} alkyl branched or unbranched, C_{3-10} cycloalkyl, C_{5-7} cycloalkenyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-3} alkoxy, NR_8R_9 , ureido, guanidino, NR_8COR_{10} , SR_{10} , $CONR_8R_9$, CO_2R_{10} , C_{3-10} cycloalkyl, C_{3-10} cycloalkylidene, C_{5-7} cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
- 20 wherein each of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkylidene, C_{5-7} cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CN, NO_2 , amidino, guanidino, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with
- 25 C_{1-3} alkyl, phenyl C_{0-3} alkyl, C_{1-3} alkoxy or CO_2R_{10} ;

or R_5 is selected from CO_2R_{10} , NR_8R_9 , CONR_8R_9 , aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

- 5 C_{1-3} alkoxy, halogen, NO_2 , CN , $\text{S}(\text{O})_p\text{NR}_8\text{R}_9$, $\text{C}_{0-3}\text{alkylS}(\text{O})_p$, NR_8R_9 , $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$, $(\text{CH}_2)_n\text{CONR}_8\text{R}_9$, $\text{CO}(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C_{1-3} alkyl optionally substituted with phenyl or NR_8R_9 , wherein Z is a bridging group selected from C_{1-10} alkylene branched or unbranched, CO, $\text{S}(\text{O})_p$, O, S, NH, CONH, NHCO, COO or
- 10 OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO_2 , C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally
- 15 partially or fully halogenated;

- or R_5 is a C_{6-12} bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be
- 20 optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , ureido, guanidino, amidino, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy;

- 25 R_6 is selected from H, C_{1-6} alkyl branched or unbranched, C_{2-6} alkenyl branched or unbranched, CO_2R_{10} , C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, aryl, aryl C_{1-3} alkyl, heteroaryl and heterocyclyl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, aryl, aryl C_{1-3} alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $\text{NR}_{11}\text{R}_{12}$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_{11}\text{R}_{12}$, aryl, heteroaryl or heterocyclyl;

30

R_7 is H or C_{1-6} alkyl;

R_8 and R_9 are the same or different and are each independently selected from H, OH, CO_2R_{10} , C_{1-10} acyl branched or unbranched, C_{1-3} alkoxy, C_{1-6} alkyl branched or unbranched, C_{3-6} alkenyl, C_{3-8} cycloalkyl, aryl, aryl C_{1-3} alkyl, aroyl, heteroaryl or heterocycle; wherein
 5 said alkyl, cycloalkyl, aryl, aryl C_{1-3} alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $NR_{11}R_{12}$, $O(CH_2)_{2-4}NR_{11}R_{12}$, aryl or heteroaryl;

or R_8 and R_9 together form a 3-7 member alkylene chain completing a ring about the N
 10 atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, $S(O)_p$, $NCOR_{10}$, NCO_2R_{10} , NR_{11} or $NC(=NR_{11})NR_{11}R_{12}$; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, OH or $-(CH_2)_nNR_{11}R_{12}$;

R_{10} is selected from H, C_{1-6} alkyl, C_{3-8} cycloalkyl, wherein each alkyl or cycloalkyl is
 15 optionally substituted with phenyl, OH, C_{1-3} alkoxy, C_{1-3} alkanoyloxy or $NR_{11}R_{12}$, or R_{10} is phenyl optionally substituted with one to three C_{1-3} alkyl, C_{1-3} alkoxy, halogen, $(CH_2)_mNR_8R_9$, $(CH_2)_nCONR_8R_9$ or $O(CH_2)_{2-4}NR_8R_9$;

R_{11} and R_{12} are each independently selected from H and C_{1-6} alkyl optionally substituted
 20 with C_{1-3} alkoxy, OH or phenyl;
 or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$;

R_{13} is H or C_{1-3} alkyl;

25

P and Q are each independently CH or N;

m is 1-4;

n is 0-3;

and p is 0-2;

30

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R₄, R₅, R₆ and R₇ substituent groups may optionally be protected by a protecting group;

and the pharmaceutically acceptable derivatives thereof.

5

In one embodiment of the invention, there are provided compounds of the formula (I) as described above, and wherein:

10 Ar₁ is

a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;

b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;

15 c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl,

d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl, or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or

20
25

e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

5 wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;

R₁ and R₂ are as defined in claim 1, and R₃ is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH;

10 wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;

R₁ and R₂ are as defined in claim 1, and R₃ is H, halogen, methyl, methoxy, hydroxymethyl or OH;

15 R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

R₅ is selected from H, C₁₋₁₀alkyl branched or unbranched, C₃₋₁₀cycloalkyl, C₅₋₇cycloalkenyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆acyl, each being optionally substituted with
 20 one or more halogen, OH, oxo, CN, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₃alkoxy, NR₈R₉, ureido, guanidino, NR₈COR₁₀, SR₁₀, CONR₈R₉, CO₂R₁₀, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylidene, C₅₋₇cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle; wherein each of C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylidene, C₅₋₇cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is
 25 optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

or R_5 is selected from CO_2R_{10} , NR_8R_9 , CONR_8R_9 , aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

- 5 C_{1-3} alkoxy, halogen, NO_2 , CN , $\text{S}(\text{O})_p\text{NR}_8\text{R}_9$, $\text{C}_{0-3}\text{alkylS}(\text{O})_p$, NR_8R_9 , $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$, $(\text{CH}_2)_n\text{CONR}_8\text{R}_9$, $\text{CO}(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or $\text{C}_{1-3}\text{alkyl}$ optionally substituted with phenyl or NR_8R_9 , wherein Z is a bridging group selected from C_{1-10} alkylene branched or unbranched, CO, $\text{S}(\text{O})_p$, O, S, NH, CONH, NHCO, COO or
- 10 OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO_2 , $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, halogen, CO_2R_{10} , $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, phenyl $\text{C}_{0-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxy}$; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally
- 15 partially or fully halogenated;

- or R_5 is a C_{6-12} bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be
- 20 optionally substituted with $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, halogen, CO_2R_{10} , ureido, guanidino, amidino, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, phenyl $\text{C}_{0-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxy}$;

- 25 R_6 is selected from H, $\text{C}_{1-6}\text{alkyl}$ branched or unbranched, C_{2-6} alkenyl branched or unbranched, or CO_2R_{10} ; wherein said $\text{C}_{1-6}\text{alkyl}$ or C_{1-6} alkenyl are optionally substituted with OH, $\text{C}_{1-3}\text{alkoxy}$, $\text{C}_{1-3}\text{acyloxy}$, CO_2R_{10} , $\text{NR}_{11}\text{R}_{12}$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_{11}\text{R}_{12}$, aryl, heteroaryl or heterocyclyl;

- 30 R_7 is H or $\text{C}_{1-6}\text{alkyl}$;

R_8 and R_9 are the same or different and are each independently selected from H, OH, C_{1-3} alkyl branched or unbranched, CO_2R_{10} , C_{3-8} cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $NR_{11}R_{12}$, $O(CH_2)_{2-4}NR_{11}R_{12}$, aryl or heteroaryl;

or R_8 and R_9 together form a 3-7 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, $S(O)_p$, $NCOR_{10}$, NCO_2R_{10} , NR_{11} or $NC(=NR_{11})NR_{11}R_{12}$; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, OH or $-(CH_2)_nNR_{11}R_{12}$;

R_{10} is H or C_{1-6} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy, C_{1-3} alkanoyloxy or $NR_{11}R_{12}$;

R_{11} and R_{12} are each independently selected from H and C_{1-6} alkyl optionally substituted with C_{1-3} alkoxy, OH or phenyl;

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$;

R_{13} is H; and

P and Q are each CH.

In another embodiment of the invention, there are provided compounds of the formula (I) as described immediately above, and wherein:

Ar_1 is phenyl or pyridyl, each optionally substituted by one or more R_1 , R_2 and R_3 ;

X is NH or N- C_{1-3} alkyl;

Y is NH;

R₁ and R₂ are the same or different and selected from: halogen, C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally partially or fully halogenated, NO₂ or NR₈R₉;

5

R₃ is H, halogen, methyl or methoxy;

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉ or CO₂R₁₀;

10

R₅ is selected from H, C₁₋₃alkyl branched or unbranched, C₃₋₈ cycloalkyl, C₅₋₇cycloalkenyl or C₂₋₄ alkenyl, each being optionally substituted with one or more OH, CN, NR₈R₉, CONR₈R₉, C₃₋₈ cycloalkyl, C₅₋₇cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with
 15 one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

20 or R₅ is selected from CO₂R₁₀, NR₈R₉, CONR₈R₉, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-
 25 hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

halogen, NO₂, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-,
 30 heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl optionally substituted with phenyl or NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched, O,

S(O)_p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, C₁₋₃alkoxy, CO₂R₁₀, (CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy; and
 5 wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R₅ is a C₆₋₇ bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be
 10 replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

R₆ is selected from H, C₁₋₆alkyl branched or unbranched or CO₂R₁₀;

15 R₇ is H or C₁₋₆alkyl;

R₈ and R₉ are the same or different and are each independently selected from H, C₁₋₃alkyl branched or unbranched, CO₂R₁₀, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C₁₋₃alkoxy;

20 or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂- group, a -(CH₂)₂-N(COR₁₀)-(CH₂)₂- group, a - (CH₂)₂-N(R₁₁)-(CH₂)₂- group or a -(CH₂)₂-N(C(=NR₁₁)NR₁₁R₁₂)-(CH₂)₂- group; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, or OH;

25 R₁₀ is H or C₁₋₆alkyl optionally substituted with phenyl, OH, C₁₋₃alkoxy, C₁₋₃alkanoyloxy or NR₁₁R₁₂;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₃ alkyl optionally
 30 substituted with C₁₋₃alkoxy or OH;

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$.

- 5 In yet another embodiment of the invention there are provided compounds of the formula (I) as described immediately above, and wherein:

Ar_1 is phenyl;

- 10 R_1 and R_2 are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, NO_2 and NH_2 ;

R_3 is H, chloro, fluoro, bromo or methoxy;

- 15 R_5 is selected from C_{2-4} alkenyl, C_{3-8} cycloalkyl or C_{5-7} cycloalkenyl, each being optionally substituted with one or more OH, CN, NR_8R_9 , $CONR_8R_9$ or phenyl; wherein phenyl is optionally substituted with one or more C_{1-3} alkyl, C_{1-3} alkoxy, halogen, amidino, guanidino, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with
20 C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy;

- or R_5 is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, or indolyl-CO- is optionally substituted with one to two:
25

- halogen, NO_2 , $SO_2NR_8R_9$, NR_8R_9 , $(CH_2)_nCO_2R_{10}$, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C_{1-3} alkyl
30 optionally substituted with NR_8R_9 , wherein Z is a bridging group selected from C_{1-3} alkylene branched or unbranched, wherein each cycloalkyl, phenyl, heteroaryl or

heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, CO₂R₁₀, NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

5

or R₅ is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

10

R₆ is selected from H or C₁₋₃alkyl branched or unbranched;

R₇ is H or C₁₋₃alkyl;


R₈ and R₉ are the same or different and are each independently selected from H or
15 C₁₋₃alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or C₁₋₃alkoxy;

or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂- , a -(CH₂)₂-N(COR₁₀)-
(CH₂)₂- group, a - (CH₂)₂-N(R₁₁)-(CH₂)₂- group or a -(CH₂)₂-N(C(=NR₁₁)NR₁₁R₁₂)-
20 (CH₂)₂- group; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, or OH;

R₁₀ is H or C₁₋₃alkyl optionally substituted with phenyl, OH or C₁₋₃alkanoyloxy;
and

R₁₁ is selected from H and C₁₋₃ alkyl.


25 In yet another embodiment of the invention, there are provided any of the compounds of formula (I) described above wherein Het represents a fused ring having formula B:



B

In still another embodiment of the invention, there are provided compounds of the formula (I') below:

5



(I')

wherein:


10 X is NH, N-C₁₋₃alkyl, N-cyclopropyl, S or O;

R₁ and R₂ are the same or different and are selected from H, halogen, CN, NO₂, C₁₋₁₀ branched or unbranched saturated or unsaturated alkyl, C₁₋₁₀ branched or unbranched alkoxy, C₁₋₁₀ branched or unbranched acyl, C₁₋₁₀ branched or unbranched acyloxy, C₁₋₁₀ branched or unbranched alkylthio, aminosulfonyl, di-(C₁₋₃)alkylaminosulfonyl, NR₈R₉, aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the above-mentioned R₁ and R₂ are optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH, NR₈R₉, C₁₋₆ branched or unbranched alkyl, C₃₋₇cycloalkyl, phenyl, naphthyl, heteroaryl, aminocarbonyl and mono- or di-(C₁₋₃)alkylaminocarbonyl;

20

R_3 is selected from the group consisting of H, halogen, OH, $(CH_2)_nNR_8R_9$, $(CH_2)_nCO_2R_{10}$, C_{1-3} alkyl optionally substituted with OH, C_{1-3} alkoxy optionally halogenated and C_{1-3} alkylthio;

- 5 Het represents a fused heterocyclic ring having a formula A, B or C:



- R_4 is selected from H, C_{1-6} alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C_{1-3} alkoxy, C_{3-10} -cycloalkyl, or C_{5-8} cycloalkenyl;
- 10 or R_4 is selected from $(CH_2)_mNR_8R_9$, $(CH_2)_mNR_8COR_{10}$, $(CH_2)_nCO_2R_{10}$, $(CH_2)_nCONR_8R_9$, phenyl, heteroaryl or heterocycle, each phenyl, heteroaryl or heterocycle being optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, $(CH_2)_mNR_8R_9$, OH, SO_3H or halogen;
- 15 R_5 is selected from H, C_{1-10} alkyl branched or unbranched, C_{3-10} cycloalkyl, C_{5-7} cycloalkenyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-3} alkoxy, NR_8R_9 , ureido, guanidino, NR_8COR_{10} , SR_{10} , $CONR_8R_9$, CO_2R_{10} , C_{3-10} cycloalkyl, C_{3-10} cycloalkylidene, C_{5-7} cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
- 20 wherein each of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkylidene, C_{5-7} cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CN, NO_2 , amidino, guanidino, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with
- 25 C_{1-3} alkyl, phenyl, C_{0-3} alkyl, C_{1-3} alkoxy or CO_2R_{10} ;

or R_5 is selected from CO_2R_{10} , NR_8R_9 , CONR_8R_9 , aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

- 5 C_{1-3} alkoxy, halogen, NO_2 , CN , $\text{S}(\text{O})_p\text{NR}_8\text{R}_9$, $\text{C}_{0-3}\text{alkylS}(\text{O})_p$, NR_8R_9 , $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$, $(\text{CH}_2)_n\text{CONR}_8\text{R}_9$, $\text{CO}(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C_{1-3} alkyl optionally substituted with phenyl or NR_8R_9 , wherein Z is a bridging group selected from C_{1-10} alkylene branched or unbranched, CO, $\text{S}(\text{O})_p$, O, S, NH, CONH, NHCO, COO or
- 10 OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO_2 , C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally
- 15 partially or fully halogenated;

- or R_5 is a C_{6-12} bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be
- 20 optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , ureido, guanidino, amidino, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy;

- 25 R_6 is selected from H, C_{1-6} alkyl branched or unbranched, C_{2-6} alkenyl branched or unbranched, CO_2R_{10} , C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, aryl, aryl C_{1-3} alkyl, heteroaryl and heterocyclyl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, aryl, aryl C_{1-3} alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $\text{NR}_{11}\text{R}_{12}$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_{11}\text{R}_{12}$, aryl, heteroaryl or heterocyclyl;

30

R_7 is H or C_{1-6} alkyl;

R_8 and R_9 are the same or different and are each independently selected from H, OH, CO_2R_{10} , C_{1-10} acyl branched or unbranched, C_{1-3} alkoxy, C_{1-6} alkyl branched or unbranched, C_{3-6} alkenyl, C_{3-8} cycloalkyl, aryl, aryl C_{1-3} alkyl, aroyl, heteroaryl or heterocycle; wherein
 5 said alkyl, cycloalkyl, aryl, aryl C_{1-3} alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $NR_{11}R_{12}$, $O(CH_2)_{2-4}NR_{11}R_{12}$, aryl or heteroaryl;

or R_8 and R_9 together form a 3-7 member alkylene chain completing a ring about the N
 10 atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, $S(O)_p$, $NCOR_{10}$, NCO_2R_{10} , NR_{11} or $NC(=NR_{11})NR_{11}R_{12}$; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, OH or $-(CH_2)_nNR_{11}R_{12}$;

R_{10} is selected from H, C_{1-6} alkyl, C_{3-8} cycloalkyl, wherein each alkyl or cycloalkyl is
 15 optionally substituted with phenyl, OH, C_{1-3} alkoxy, C_{1-3} alkanoyloxy or $NR_{11}R_{12}$, or R_{10} is phenyl optionally substituted with one to three C_{1-3} alkyl, C_{1-3} alkoxy, halogen, $(CH_2)_mNR_8R_9$, $(CH_2)_nCONR_8R_9$ or $O(CH_2)_{2-4}NR_8R_9$;

R_{11} and R_{12} are each independently selected from H and C_{1-6} alkyl optionally substituted
 20 with C_{1-3} alkoxy, OH or phenyl;
 or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$;

R_{13} is H or C_{1-3} alkyl;

25

P and Q are each independently CH or N;

m is 1-4;

n is 0-3;

and p is 0-2;

30

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the R_4 , R_5 , R_6 and R_7 substituent groups may optionally be protected by a protecting group;

and the pharmaceutically acceptable derivatives thereof.

5

In another embodiment of the invention there are provided compounds of the formula(I') as described above, and wherein:

X is NH or N- C_{1-3} alkyl;

10

R_1 and R_2 are the same or different and selected from: halogen, C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally partially or fully halogenated, NO_2 or NR_8R_9 ;

R_3 is H, halogen, methyl or methoxy;

15

R_4 is H, C_{1-3} alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R_4 is $(CH_2)_{2-3}NR_8R_9$ or CO_2R_{10} ;

R_5 is selected from H, C_{1-3} alkyl branched or unbranched, C_{3-8} cycloalkyl, C_{5-7} cycloalkenyl or C_{2-4} alkenyl, each being optionally substituted with one or more OH, CN, NR_8R_9 , $CONR_8R_9$, C_{3-8} cycloalkyl, C_{5-7} cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CN, NO_2 , amidino, guanidino, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the amidino or
25 guanidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl, C_{0-3} alkyl, C_{1-3} alkoxy or CO_2R_{10} ;

or R_5 is selected from CO_2R_{10} , NR_8R_9 , $CONR_8R_9$, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-
30 pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl,

benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

5 halogen, NO₂, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl optionally substituted with phenyl or NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched, O, S(O)_p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally
 10 substituted with NO₂, C₁₋₃alkyl, C₁₋₃alkoxy, CO₂R₁₀, (CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

15 or R₅ is a C₆₋₇ bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

20 R₆ is selected from H, C₁₋₆alkyl branched or unbranched or CO₂R₁₀;

R₇ is H or C₁₋₆alkyl;

25 R₈ and R₉ are the same or different and are each independently selected from H, C₁₋₃alkyl branched or unbranched, CO₂R₁₀, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C₁₋₃alkoxy;

30 or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂- group, a -(CH₂)₂-N(COR₁₀)-(CH₂)₂- group, a - (CH₂)₂-N(R₁₁)-(CH₂)₂- group or a -(CH₂)₂-

$N(C(=NR_{11})NR_{11}R_{12})-(CH_2)_2$ - group; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, or OH;

R_{10} is H or C_{1-6} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy, C_{1-3} alkanoyloxy or $NR_{11}R_{12}$;

R_{11} and R_{12} are each independently selected from H and C_{1-3} alkyl optionally substituted with C_{1-3} alkoxy or OH;

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$; and

P and Q are each CH.

In still a further embodiment of the invention there are provided compounds of the formula (I') as described immediately above, and wherein:

R_1 and R_2 are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, NO_2 and NH_2 ;

R_3 is H, chloro, fluoro, bromo or methoxy;

20

R_5 is selected from C_{2-4} alkenyl, C_{3-8} cycloalkyl or C_{5-7} cycloalkenyl, each being optionally substituted with one or more OH, CN, NR_8R_9 , $CONR_8R_9$ or phenyl; wherein phenyl is optionally substituted with one or more C_{1-3} alkyl, C_{1-3} alkoxy, halogen, amidino, guanidino, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy;

25

or R_5 is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl,

30

thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

halogen, NO₂, SO₂NR₈R₉, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, cycloalkyl, phenyl,
 5 heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C₁₋₃alkyl
 optionally substituted with NR₈R₉, wherein Z is a bridging group selected from C₁₋₃
 alkylene branched or unbranched or S(O)_p, wherein each cycloalkyl, phenyl, heteroaryl or
 heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, CO₂R₁₀, NR₈R₉ or guanidino,
 wherein one or more of the amino nitrogens in the guanidino group in this paragraph may
 10 be optionally substituted with C₁₋₃alkyl; and wherein each alkyl and phenyl in this
 paragraph is optionally partially or fully halogenated;

or R₅ is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two
 double bonds in the ring system, wherein said ring system may be optionally substituted
 15 with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

R₆ is selected from H or C₁₋₃alkyl branched or unbranched,

R₇ is H or C₁₋₃alkyl;

20


R₈ and R₉ are the same or different and are each independently selected from H or
 C₁₋₃alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or
 C₁₋₃alkoxy;

25 or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂-, a -(CH₂)₂-N(COR₁₀)-
 (CH₂)₂- group, a - (CH₂)₂-N(R₁₁)-(CH₂)₂- group or a -(CH₂)₂-N(C(=NR₁₁)NR₁₁R₁₂)-
 (CH₂)₂- group; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, or
 OH;

30 R₁₀ is H or C₁₋₃alkyl optionally substituted with phenyl, OH or C₁₋₃alkanoyloxy;
 and

R_{11} is selected from H and C_{1-3} alkyl.


In yet another embodiment of the invention, there are provided any of the compounds of formula (I') described above wherein Het represents a fused ring having formula B:



B

5

In yet another aspect of the invention, there are provided compounds of the following formula Ib:




Ib

10 wherein R is H, C_{1-3} alkyl or cyclopropyl, and Ar_1 and R_5 are as defined in formula (I) above.

The present invention is also directed to the intermediate compounds of the following formulae (VI), (XII), (XVIII) and (XIX) useful in the synthetic schemes and examples set
15 forth below.

20 **Formula (VI)**

In their broadest generic aspect, intermediate compounds of the formula (VI) are represented by the following formula:



VI

wherein:

5 R is H, C₁₋₃alkyl or cyclopropyl;

R₄ is selected from H, C₁₋₆ alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C₁₋₃alkoxy; or R₄ is selected from (CH₂)_mNR₈R₉, (CH₂)_mNR₈COR₁₀, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

10

R₈ and R₉ are the same or different and are each independently selected from H, OH, CO₂R₁₀, C₁₋₁₀ acyl branched or unbranched, C₁₋₃alkoxy, C₁₋₆alkyl branched or unbranched, C₃₋₆alkenyl, C₃₋₈cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;

15

or R₈ and R₉ together form a 3-7 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)_p, NCOR₁₀, NCO₂R₁₀, NR₁₁ or NC(=NR₁₁)NR₁₁R₁₂; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;

20

R₁₀ is selected from H, C₁₋₆alkyl, C₃₋₈cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C₁₋₃alkoxy, C₁₋₃alkanoyloxy or NR₁₁R₁₂, or R₁₀ is

phenyl optionally substituted with one to three C_{1-3} alkyl, C_{1-3} alkoxy, halogen,
 $(CH_2)_mNR_8R_9$, $(CH_2)_nCONR_8R_9$ or $O(CH_2)_{2-4}NR_8R_9$;

R_{11} and R_{12} are each independently selected from H and C_{1-6} alkyl optionally substituted
 5 with C_{1-3} alkoxy, OH or phenyl;
 or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or
 $(CH_2)_2O(CH_2)_2$;

m is 1-4;
 10 n is 1-3;
 and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in the R_4
 substituent group may optionally be protected by a protecting group.

15

One embodiment of the compounds of formula(VI) are those wherein:


R is H or C_{1-3} alkyl; and

R_4 is H, C_{1-3} alkyl branched or unbranched, saturated or unsaturated, and optionally
 20 substituted with OH; or R_4 is $(CH_2)_{2-3}NR_8R_9$, $(CH_2)_nCO_2R_{10}$ or $(CH_2)_nCONR_8R_9$.

Formula (XII)

In their broadest generic aspect, intermediate compounds of formula (XII) are represented
 by the following formula:

25



XII

wherein:

R is H, C₁₋₃alkyl or cyclopropyl; and

- 5 R₅ is selected from H, C₁₋₁₀alkyl branched or unbranched, C₃₋₁₀ cycloalkyl, C₅₋₇cycloalkenyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆acyl, each being optionally substituted with one or more halogen, OH, oxo, CN, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₃alkoxy, NR₈R₉, ureido, guanidino, NR₈COR₁₀, SR₁₀, CONR₈R₉, CO₂R₁₀, C₃₋₁₀ cycloalkyl, C₃₋₁₀cycloalkylidene, C₅₋₇cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle;
- 10 wherein each of C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylidene, C₅₋₇cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted
- 15 with C₁₋₃alkyl, phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

or R₅ is selected from CO₂R₁₀, NR₈R₉, CONR₈R₉, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

- 20 C₁₋₃alkoxy, halogen, NO₂, CN, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀, (CH₂)_nCONR₈R₉, CO(CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl optionally substituted with phenyl or NR₈R₉, wherein Z is a bridging group selected from
- 25 C₁₋₁₀ alkylene branched or unbranched, CO, S(O)_p, O, S, NH, CONH, NHCO, COO or OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CO₂R₁₀, (CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or
- 30 C₁₋₃alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

- or R_5 is a C_{6-12} bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be
- 5 optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , ureido, guanidino, amidino, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy;
- 10 R_6 is selected from H, C_{1-6} alkyl branched or unbranched, C_{2-6} alkenyl branched or unbranched, CO_2R_{10} , C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, aryl, aryl C_{1-3} alkyl, heteroaryl and heterocyclyl; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl, aryl, aryl C_{1-3} alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $NR_{11}R_{12}$, $O(CH_2)_{2-4}NR_{11}R_{12}$, aryl, heteroaryl or heterocyclyl;
- 15 R_7 is H or C_{1-6} alkyl;
- R_8 and R_9 are the same or different and are each independently selected from H, OH, CO_2R_{10} , C_{1-10} acyl branched or unbranched, C_{1-3} alkoxy, C_{1-6} alkyl branched or unbranched,
- 20 C_{3-6} alkenyl, C_{3-8} cycloalkyl, aryl, aryl C_{1-3} alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, aryl C_{1-3} alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $NR_{11}R_{12}$, $O(CH_2)_{2-4}NR_{11}R_{12}$, aryl or heteroaryl;
- 25 or R_8 and R_9 together form a 3-7 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, $S(O)_p$, $NCOR_{10}$, NCO_2R_{10} , NR_{11} or $NC(=NR_{11})NR_{11}R_{12}$; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, OH or $-(CH_2)_nNR_{11}R_{12}$;
- 30 R_{10} is selected from H, C_{1-6} alkyl, C_{3-8} cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C_{1-3} alkoxy, C_{1-3} alkanoyloxy or $NR_{11}R_{12}$, or R_{10} is

phenyl optionally substituted with one to three C₁₋₃alkyl, C₁₋₃alkoxy, halogen,
(CH₂)_mNR₈R₉, (CH₂)_nCONR₈R₉ or O(CH₂)₂₋₄NR₈R₉;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted
5 with C₁₋₃alkoxy, OH or phenyl;
or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or
(CH₂)₂O(CH₂)₂;

m is 1-4;
10 n is 0-3;
and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the
R₄, R₅, R₆ and R₇ substituent groups may optionally be protected by a protecting group.

15

One embodiment of the compounds of formula (XII) are those wherein:

R is H or C₁₋₃alkyl; and

20 R₅ is selected from H, C₁₋₃alkyl branched or unbranched, C₃₋₈ cycloalkyl,
C₅₋₇cycloalkenyl or C₂₋₄ alkenyl, each being optionally substituted with one or more OH,
CN, NR₈R₉, CONR₈R₉, C₃₋₈ cycloalkyl, C₅₋₇cycloalkenyl, phenyl, heteroaryl or
heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with
one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉,
25 or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the amidino or
guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl,
phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

or R₅ is selected from CO₂R₁₀, NR₈R₉, CONR₈R₉, phenyl, furyl, thienyl, oxazolyl,
30 thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-
pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-

CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

5

halogen, NO₂, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl optionally substituted with phenyl or NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched, O, S(O)_p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, C₁₋₃alkoxy, CO₂R₁₀, (CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

10
15

or R₅ is a C₆₋₇ bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

20

Yet another embodiment of the compounds of formula (XII) are those described immediately above, wherein:

R₅ is selected from C₂₋₄ alkenyl, C₃₋₈ cycloalkyl or C₅₋₇cycloalkenyl, each being optionally substituted with one or more OH, CN, NR₈R₉, CONR₈R₉ or phenyl; wherein phenyl is optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy;

25
30

or R₅ is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:


halogen, NO₂, SO₂NR₈R₉, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C₁₋₃alkyl optionally substituted with NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched or S(O)_p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, CO₂R₁₀, NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

15

or R₅ is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

20 Formula (XVIII)

In their broadest generic aspect, intermediate compounds of the formula (XVIII) are represented by the following formula:



XVIII

25

wherein:

Ar₁ is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle; wherein said carbocycle, heteroaryl or heterocycle is optionally substituted by one or more R₁, R₂ and R₃;

5 R is H, C₁₋₃alkyl or cyclopropyl;

R₁ and R₂ are the same or different and are selected from H, halogen, CN, NO₂, C₁₋₁₀ branched or unbranched saturated or unsaturated alkyl, C₁₋₁₀ branched or unbranched alkoxy, C₁₋₁₀ branched or unbranched acyl, C₁₋₁₀ branched or unbranched acyloxy, C₁₋₁₀ branched or unbranched alkylthio, aminosulfonyl, di-(C₁₋₃)alkylaminosulfonyl, NR₈R₉,
 10 aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the abovementioned R₁ and R₂ are optionally partially or fully halogenated or optionally substituted with one to three groups independently selected from the group consisting of oxo, OH, NR₈R₉, C₁₋₆ branched or unbranched alkyl, C₃₋₇cycloalkyl, phenyl, naphthyl,
 15 heteroaryl, aminocarbonyl and mono- or di(C₁₋₃)alkylaminocarbonyl;

R₃ is selected from the group consisting of H, halogen, OH, (CH₂)_nNR₈R₉, (CH₂)_nCO₂R₁₀, C₁₋₃alkyl optionally substituted with OH, C₁₋₃ alkoxy optionally halogenated and C₁₋₃ alkylthio;

20

R₄ is selected from H, C₁₋₆ alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C₁₋₃alkoxy, C₃₋₁₀-cycloalkyl, or C₅₋₈cycloalkenyl; or R₄ is selected from (CH₂)_mNR₈R₉, (CH₂)_mNR₈COR₁₀, (CH₂)_nCO₂R₁₀, (CH₂)_nCONR₈R₉, phenyl, heteroaryl or heterocycle, each phenyl, heteroaryl or heterocycle being optionally
 25 substituted with C₁₋₃alkyl, C₁₋₃alkoxy, (CH₂)_mNR₈R₉, OH, SO₃H or halogen;

R₈ and R₉ are the same or different and are each independently selected from H, OH, CO₂R₁₀, C₁₋₁₀ acyl branched or unbranched, C₁₋₃alkoxy, C₁₋₆alkyl branched or unbranched, C₃₋₆alkenyl, C₃₋₈cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle; wherein
 30 said alkyl, cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle are optionally

substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;

or R₈ and R₉ together form a 3-7 member alkylene chain completing a ring about the N
5 atom to which they are attached; wherein said alkylene chain is optionally interrupted by
O, S(O)_p, NCOR₁₀, NCO₂R₁₀, NR₁₁ or NC(=NR₁₁)NR₁₁R₁₂; and wherein said ring is
optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;
R₁₀ is selected from H, C₁₋₆alkyl, C₃₋₈cycloalkyl, wherein each alkyl or cycloalkyl is
optionally substituted with phenyl, OH, C₁₋₃alkoxy, C₁₋₃alkanoyloxy or NR₁₁R₁₂, or R₁₀ is
10 phenyl optionally substituted with one to three C₁₋₃alkyl, C₁₋₃alkoxy, halogen,
(CH₂)_mNR₈R₉, (CH₂)_nCONR₈R₉ or O(CH₂)₂₋₄NR₈R₉;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted
with C₁₋₃alkoxy, OH or phenyl;
15 or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or
(CH₂)₂O(CH₂)₂;

m is 1-4;

n is 0-3;

20 and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the
R₄, R₅, R₆ and R₇ substituent groups may optionally be protected by a protecting group.

25 One embodiment of the compounds of formula (XVIII) are those wherein:

Ar₁ is

- a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl,
cyclohexanyl and cycloheptanyl;
- 30 b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and
cycloheptenyl;

c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl,

d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinoliny, isoquinoliny, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl, or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or

e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;

R₁ and R₂ are as defined in claim 1, and R₃ is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

R₈ and R₉ are the same or different and are each independently selected from H, OH, C₁₋₃alkyl branched or unbranched, CO₂R₁₀, C₃₋₈cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl,

heteroaryl or heterocycle are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;

5 or R₈ and R₉ together form a 4-6 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by NCO₂R₁₀ or NR₁₁; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;

10 R₁₀ is H or C₁₋₆alkyl optionally substituted with phenyl, OH, C₁₋₃alkoxy or NR₁₁R₁₂;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted with C₁₋₃alkoxy, OH or phenyl;

15 or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or (CH₂)₂O(CH₂)₂; and

n is 0-3.

20 Yet another embodiment of the compounds of formula (XVIII) are those described immediately above, wherein:

Ar₁ is phenyl or pyridyl, each optionally substituted by one or more R₁, R₂ and R₃;

25 R is H or C₁₋₃alkyl;

R₁ and R₂ are the same or different and selected from: halogen, C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally partially or fully halogenated, NO₂ or NR₈R₉;

30 R₃ is H, halogen, methyl or methoxy;

R_4 is H, C_{1-3} alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R_4 is $(CH_2)_{2-3}NR_8R_9$ or CO_2R_{10} ;

R_8 and R_9 are the same or different and are each independently selected from H, C_{1-3} alkyl branched or unbranched, CO_2R_{10} , phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C_{1-3} alkoxy;

or R_8 and R_9 together form a $-(CH_2)_2-N(CO_2R_{10})-(CH_2)_2-$ group or a $-(CH_2)_2-N(R_{11})-(CH_2)_2-$ group; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, or OH;


R_{10} is H or C_{1-3} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy or $NR_{11}R_{12}$;

R_{11} and R_{12} are each independently selected from H and C_{1-3} alkyl optionally substituted with C_{1-3} alkoxy or OH;

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$.

Formula (XIX)

In their broadest generic aspect, intermediate compounds of formula (XIX) are represented by the following formula:



XIX

wherein:

Ar₁ is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle; wherein said carbocycle, heteroaryl or heterocycle is optionally substituted by one or more R₁, R₂ and
5 R₃;

R is H, C₁₋₃alkyl or cyclopropyl

R₁ and R₂ are the same or different and are selected from H, halogen, CN, NO₂, C₁₋₁₀
10 branched or unbranched saturated or unsaturated alkyl, C₁₋₁₀ branched or unbranched
alkoxy, C₁₋₁₀ branched or unbranched acyl, C₁₋₁₀ branched or unbranched acyloxy, C₁₋₁₀
branched or unbranched alkylthio, aminosulfonyl, di-(C₁₋₃)alkylaminosulfonyl, NR₈R₉,
aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the
abovementioned R₁ and R₂ are optionally partially or fully halogenated or optionally
15 substituted with one to three groups independently selected from the group consisting of
oxo, OH, NR₈R₉, C₁₋₆ branched or unbranched alkyl, C₃₋₇cycloalkyl, phenyl, naphthyl,
heteroaryl, aminocarbonyl and mono- or di-(C₁₋₃)alkylaminocarbonyl;

R₃ is selected from the group consisting of H, halogen, OH, (CH₂)_nNR₈R₉, (CH₂)_nCO₂R₁₀,
20 C₁₋₃alkyl optionally substituted with OH, C₁₋₃ alkoxy optionally halogenated and C₁₋₃
alkylthio;

R₄ is selected from H, C₁₋₆ alkyl branched or unbranched, saturated or unsaturated, and
optionally substituted with phenyl, OH or C₁₋₃alkoxy, C₃₋₁₀-cycloalkyl, or C₅₋₈cycloalkenyl;
25 or R₄ is selected from (CH₂)_mNR₈R₉, (CH₂)_mNR₈COR₁₀, (CH₂)_nCO₂R₁₀, (CH₂)_nCONR₈R₉,
phenyl, heteroaryl or heterocycle, each phenyl, heteroaryl or heterocycle being optionally
substituted with C₁₋₃alkyl, C₁₋₃alkoxy, (CH₂)_mNR₈R₉, OH, SO₃H or halogen;

R₈ and R₉ are the same or different and are each independently selected from H, OH,
30 CO₂R₁₀, C₁₋₁₀ acyl branched or unbranched, C₁₋₃alkoxy, C₁₋₆alkyl branched or unbranched,
C₃₋₆alkenyl, C₃₋₈cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle; wherein

said alkyl, cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;

- 5 or R₈ and R₉ together form a 3-7 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)_p, NCOR₁₀, NCO₂R₁₀, NR₁₁ or NC(=NR₁₁)NR₁₁R₁₂; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;
- 10 R₁₀ is selected from H, C₁₋₆alkyl, C₃₋₈cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C₁₋₃alkoxy, C₁₋₃alkanoyloxy or NR₁₁R₁₂, or R₁₀ is phenyl optionally substituted with one to three C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_mNR₈R₉, (CH₂)_nCONR₈R₉ or O(CH₂)₂₋₄NR₈R₉;
- 15 R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted with C₁₋₃alkoxy, OH or phenyl;
or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or (CH₂)₂O(CH₂)₂;
- 20 m is 1-4;
n is 0-3;
and p is 0-2;
- wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the
- 25 R₄, R₅, R₆ and R₇ substituent groups may optionally be protected by a protecting group.

One embodiment of the compounds of formula (XIX) above is wherein:

Ar₁ is

- 30 a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;

b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;

c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl,

5 d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl, or a fused heteroaryl selected from
 10 cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole,
 15 cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or

e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl
 20 and indolinyl;

wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;

R₁ and R₂ are as defined in claim 1, and R₃ is hydrogen, halogen, methyl, methoxy,
 25 hydroxymethyl or OH; and

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

30 R₈ and R₉ are the same or different and are each independently selected from H, OH, C₁₋₃alkyl branched or unbranched, CO₂R₁₀, C₃₋₈cycloalkyl, phenyl, benzyl, benzoyl,

heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;

- 5 or R₈ and R₉ together form a 4-6 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by NCO₂R₁₀ or NR₁₁; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;

- 10 R₁₀ is H or C₁₋₆alkyl optionally substituted with phenyl, OH, C₁₋₃alkoxy or NR₁₁R₁₂;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted with C₁₋₃alkoxy, OH or phenyl;

- 15 or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or (CH₂)₂O(CH₂)₂; and

n is 0-3.

- 20 Yet another embodiment of the compounds of formula (XIX) are those described immediately above, wherein:

Ar₁ is phenyl or pyridyl, each optionally substituted by one or more R₁, R₂ and R₃;

- 25 R is H or C₁₋₃alkyl;

R₁ and R₂ are the same or different and selected from: halogen, C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally partially or fully halogenated, NO₂ or NR₈R₉;

30

R₃ is H, halogen, methyl or methoxy;

R_4 is H, C_{1-3} alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R_4 is $(CH_2)_{2-3}NR_8R_9$ or CO_2R_{10} ;

R_8 and R_9 are the same or different and are each independently selected from H,
5 C_{1-3} alkyl branched or unbranched, CO_2R_{10} , phenyl, or benzoyl; wherein said alkyl, phenyl
or benzoyl are optionally substituted with OH or C_{1-3} alkoxy;

or R_8 and R_9 together form a - $(CH_2)_2-N(CO_2R_{10})-(CH_2)_2-$ group or a - $(CH_2)_2-$
N(R_{11})-(CH₂)₂- group; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-}
3alkoxy, or OH;

10

R_{10} is H or C_{1-3} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy or
NR₁₁R₁₂;

R_{11} and R_{12} are each independently selected from H and C_{1-3} alkyl optionally
15 substituted with C_{1-3} alkoxy or OH;

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or
 $(CH_2)_2O(CH_2)_2$.

20 In a further embodiment of the invention, there are provided the following compounds of
the formula (I):

2-(2,6-Dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

25 2-(2,6-Dichlorophenylamino)-7-furan-2-yl-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-7-phenyl-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;

30

- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-nitrophenyl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-(3-Aminophenyl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 1-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-phenyl}-3-ethylurea;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-vinyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-thiophen-2-yl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[2-(3-nitrophenyl)-thiazol-4-yl]-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-7-imidazol-2-yl-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-phenyloxazol-5-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-7-carboxamide;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methylpropen-1-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-2-yl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-3-yl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-1*H*-imidazo[4,5-*f*]quinazoline-7,9-6*H*,8*H*-dione;
2-(2,6-Dichlorophenylamino)-1-methyl-7-propen-2-yl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

10

7-Cyclopent-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

7-[2-(3-Aminophenyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

15

Ethyl 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-7-carboxylate;

7-Benzofuran-2-yl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

20

2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methylprop-1-enyl)-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

25

2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methyloxazol-5-yl)-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-7-(1*H*-indole-3-carbonyl)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

30

- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-piperazin-1-yl-cyclopent-1-enyl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-Cyclohex-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-1,2,5,6-tetrahydro-pyridin-3-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[5-(2-nitrophenyl)-furan-2-yl]-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-7-furan-3-yl-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-(5-Bromofuran-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-methylfuran-2-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-Cyclopropyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(4-methylpiperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-cyclopent-2-enyl}-piperazine-1-carboxylic acid *tert*-butyl ester;
- 2-(2,6-Dichlorophenylamino)-7-(3-hydroxycyclopent-1-enyl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(piperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 5 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-cyclopent-3-enecarbonitrile;
- 7-Amino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 10 3-{2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-propenyl}-benzonitrile;
- 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-cyclopent-3-enecarboxamide;
- 15 2-{4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-thiazol-2-yl}-pyrrolidine-1-carboxylic acid benzyl ester;
- 20 2-(2,6-Dichlorophenylamino)-1-methyl-7-[1-methyl-2-(3-nitrophenyl)-vinyl]-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 3-{4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-thiazol-2-ylmethyl}-piperidine-1-carboxylic acid benzyl ester;
- 25 7-[2-(2-Aminocyclohexyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-piperidin-3-ylmethyl-thiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 30

- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methylthiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-oxocyclopent-1-enyl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-2,5-dihydro-pyrrole-1-carboxylic acid *tert*-butyl ester;
- 7-[2-(3-Aminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- Acetic acid 2-(4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-benzenesulfonyl}-piperazin-1-yl)-2-oxoethyl ester;
- 2-(2,6-Dichlorophenylamino)-7-(2,5-dihydro-1H-pyrrol-3-yl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-[2-(3-Aminomethylphenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-benzenesulfonyl}-piperazine-1-carboxamidine;
- 2-(2,6-Dichlorophenylamino)-7-{3-[4-(2-hydroxyacetyl)-piperazine-1-sulfonyl]-phenyl}-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 3-{2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-propenyl}-benzamidine;

7-(7-Azabicyclo[2.2.1]hepta-2,5-dien-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

5 5-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-3,3a,4,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylic acid *tert*-butyl ester;

2-(2,6-Dichlorophenylamino)-7-(1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrol-5-yl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

10

2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-pyrrolidin-2-yl-thiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

15 7-[2-(3,5-Diaminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one; and

2-(2,6-Dichlorophenylamino)-1-methyl-7-[4-(piperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one; and

20 the pharmaceutically acceptable derivatives thereof.

Any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly
25 included in the present invention. Each stereogenic carbon may be in the R or S configuration, or a combination of configurations.

Some of the compounds of the invention can exist in more than one tautomeric form. The invention includes all such tautomers.

The compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art. For example, a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by the invention.

All terms as used herein in this specification, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. For example, "C₁₋₆alkoxy" is a C₁₋₆alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, pentoxy and hexoxy. All alkyl, alkylene or alkynyl groups shall be understood as being branched or unbranched unless otherwise specified. Other more specific definitions are as follows:

The term "halogen" as used in the present specification shall be understood to mean bromine, chlorine, fluorine or iodine.

The term "heteroaryl" refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic aromatic heterocycle radical. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached by any atom of the cycle, which results in the creation of a stable structure. Example "heteroaryl" radicals include, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl and indazolyl, or a fused heteroaryl such as cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole,

cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanthiophene and cyclohexanthiophene;

The term "heterocycle" refers to a stable 5-8 membered (but preferably, 5 or 6 membered) monocyclic or 8-11 membered bicyclic heterocycle radical which may be either saturated or unsaturated, and is non-aromatic. Each heterocycle consists of carbon atoms and from 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be attached to the main structure by any atom of the cycle, which results in the creation of a stable structure. Example "heterocycle" radicals include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, 1,2,5,6-tetrahydropyridinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl, indolinyl, and 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl.

As used herein and throughout this specification, the terms "nitrogen" and "sulfur" and their respective elements symbols include any oxidized form of nitrogen and sulfur and the quaternized form of any basic nitrogen.

The term "aryl" shall be understood to mean a 6-10 membered aromatic carbocycle, "aryl" includes, for example, phenyl and naphthyl; other terms comprising "aryl" will have the same definition for the aryl component, examples of these moieties include: arylalkyl, aryloxy or arylthio.

The term "carbocycle" shall be understood to mean a 3-10 membered aromatic or nonaromatic cyclic carbon chain. Examples of nonaromatic carbocycles include cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl; cycloalkylidene groups such as cyclopentylidene, cyclohexylidene; and cycloalkenyl groups such as cyclopentenyl, cyclohexenyl and cycloheptenyl. Examples of aromatic carbocycles include the "aryl" compounds as described hereinabove.

The "C₆₋₁₂ bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be

replaced by heteroatoms selected from N, O and S" in the R₅ definition shall be understood to mean any ring system containing 6 to 12 carbon atoms and having at least one bridged-type or spiro-type fusion within the ring system, wherein up to 3 of the aforementioned carbon atoms may optionally be replaced by a heteroatom independently selected from N, O and S. An example is a C₆₋₁₀, preferably, C₆₋₇ bridged-bicyclic ring system, optionally having one or two double bonds in the system, wherein up to 2, preferably up to 1, carbon atoms in the ring system are replaced by a nitrogen atom. An example of such a ring system is 7-azabicyclo[2.2.1]hept-2,5-diene. Other examples within the broad definition include norbornenyl, tropanyl, 1-azabicyclo[2.2.2]oct-2-enyl, 7-azabicyclo[3.2.1]oct-6-enyl, spiro[4.5]dec-1-enyl, and spiro[4.4]non-1-enyl.

The term "acyl" shall be understood to mean an R-(C=O)- moiety wherein R is an alkyl. Examples of R can be a C₁₋₁₀alkyl, saturated or unsaturated, branched or unbranched, or R can be "aryl" as defined hereinabove. An example when R is an aryl is the benzoyl group or C₆H₅-CO. "Acyloxy" shall be understood to mean an R-CO₂- group wherein R is as defined in this paragraph.

As indicated above, one or more of the primary amine or secondary amine nitrogen atoms in any of the R₄, R₅, R₆ and R₇ substituent groups may optionally be protected by a protecting group. Suitable protecting groups for this purpose, for example, are those disclosed in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Wiley, New York, 1990. Examples of suitable protecting groups for this purpose include benzyloxycarbonyl, tert-butyloxycarbonyl, allyloxycarbonyl, acetyl and trifluoroacetyl. The invention includes pharmaceutically acceptable derivatives of compounds of the invention. A "pharmaceutically acceptable derivative" refers to any pharmaceutically acceptable salt or ester of a compound of this invention, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or pharmacologically active residue thereof.

30

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of this invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C₁-C₄ alkyl)₄⁺ salts.

In addition, the compounds of this invention include prodrugs of compounds of the invention. Prodrugs include those compounds that, upon simple chemical transformation, are modified to produce a compound of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction, enzymatically, metabolically or otherwise. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a compound of the invention, thereby imparting the desired pharmacological effect.


General Synthetic Methods

The compounds of the invention may be prepared by the methods described below. In each of the schemes below, the groups R₄, R₅, R₆, R₇, R₉ and Ar₁ are as defined above for general formula I except as noted. Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC) if desired. Intermediates and products may be purified by chromatography on silica gel and/or recrystallization. Starting materials and reagents are either commercially

available or may be prepared by one skilled in the art using methods described in the chemical literature.

Compounds of formula (I) in which Het is the dione shown in formula (Ia) (Scheme 1) may be prepared as illustrated in Scheme 1 and described below (Method A).

Scheme 1 (Method A)



** preliminary step II \rightarrow IIa for when R_4 is not H

6-Chloroanthranilic acid (II) is reacted with sodium cyanate in the presence of a suitable acid, such as acetic acid, followed by a suitable base such as sodium hydroxide. Following an acidic work-up, the quinazolinedione III is isolated. In cases where R_4 is not H, one may react II ($R_4 = H$) with an appropriate aldehyde ($RCHO$) in the presence of a suitable reducing agent, such as sodium borohydride to provide IIa ($R_4 = RCH_2$).


Intermediate III is then subjected to nitration conditions, for example treatment with nitric acid in the presence of sulfuric acid to provide IV. Intermediate IV is then treated with excess amine RNH_2 ($R = H, C_{1-3}$ alkyl or cyclopropyl) in a suitable solvent, such as *n*-butanol, preferably in a sealed vessel with heating at about 50 to 150° C, to provide V.

Reduction of V, for example by treatment with hydrogen preferably at 10 – 60 psi in the presence of a suitable catalyst such as 10 % Pd/c, provides VI. Treatment of VI with the desired isothiocyanate (Ar_1NCS), in a suitable solvent such as DMF provides thiourea (VII). Cyclization of VII may be accomplished by treatment with a suitable coupling reagent, such as dicyclohexylcarbodiimide or mercury oxide in a suitable solvent such as THF or DMF to provide the desired compound Ia.

Compounds of formula (I) in which Het is substituted with R_5 as shown in formula (Ib) (Scheme 2) may be prepared as illustrated in Scheme 2 and described below (Method B).

10

Scheme 2 (Method B)




In cases where R_5 is H, one may treat 6-chloroanthranilic acid (II) with triazine in a suitable solvent, such as EtOH, in the presence of a suitable base such as piperidine, preferably while heating at about the reflux temperature of the solvent to provide the quinazolinone VIII ($\text{R}_5 = \text{H}$). to obtain compounds where R_5 is not H, one may react the amide IX with an acid chloride R_5COCl , in a suitable solvent, such as THF, in the presence of a suitable base, such as triethylamine to provide an intermediate amide which is cyclized to VIII by treatment with a suitable base, for example sodium methoxide in methanol, preferably at reflux temperature. Intermediate VIII may then be converted to Ib by the same general procedure described in Method A for a converting III to Ia.

The preparation of benzimidazole intermediates, which may be used in alternate procedures to prepare compounds of formula (I) is illustrated in Scheme 3 and described below (Method C):

5


Scheme 3 (Method C)



2,6-Dichloro-3-nitrobenzonitrile (XIII) is treated with the desired amine RNH_2 ($R = H, C_{1-3}$ alkyl or cyclopropyl) in a suitable solvent such as THF or EtOAc to provide XIV. This intermediate is then treated with R_4NH_2 in a suitable solvent such as EtOH, preferably in a sealed vessel while heating at about 50-110° C to provide XV. Reduction to XVI, formation of thiourea XVII and cyclization to benzimidazole XVIII may be carried out as described for the conversion of V to Ia in Method A. Hydrolysis of the nitrile, for example, by treatment with concentrated H_2SO_4 at about 100° C, provides XIX.

Method D (Scheme 4) illustrates how one may prepare compounds of formula (Ib) from intermediate XVIII ($R_4 = H$).

Scheme 4 (Method D)




Treatment of XVIII ($\text{R}_4 = \text{H}$) with an acid halide R_5COX (where X is a halogen) or acid anhydride $(\text{R}_5\text{CO})_2\text{O}$ or with an acid $\text{R}_5\text{CO}_2\text{H}$ and a coupling reagent such as dicyclohexylcarbodiimide or 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide, in a
 5 suitable solvent, such as THF or DMF, in the presence of a suitable base such as triethylamine or 4-(dimethylamino)pyridine provides amide XX.

Hydrolysis of the nitrile, followed by cyclization to Ib may be achieved, for example, by
 10 treatment of XX with a suitable base, such as aqueous sodium hydroxide, and an oxidant such as hydrogen peroxide or sodium perborate in a suitable solvent such as dioxane.

Intermediate XIX ($\text{R}_4 = \text{H}$) may be used to prepare compounds of formula (Ib) as outlined in Scheme 5 (Method E):


Scheme 5 (Method E)



Formation of XXI may be accomplished as described above for conversion of XVIII to XX. Intermediate XXI may then be cyclized by treatment with a suitable base such as sodium methoxide or potassium t-butoxide in a suitable solvent such as MeOH or THF, respectively, at about reflux temperature to provide Ib.

Intermediate XIX may also be used to prepare compounds of formula (Ia) as illustrated in Scheme 6 (Method F).

Scheme 6 (Method F)




10

Treatment of XIX with carbonyldiimidazole (CDI) or a phosgene equivalent in a suitable solvent such as THF provides Ia.

Compounds of formula (I) in which Het is partially saturated may be prepared from intermediate XIX, as illustrated in Scheme 7 (Method G).

Scheme 7 (Method G)




- 5 Treatment of XIX with a ketone (R₆C(O)R₇, where R₆ and R₇ are not H) in the presence of a catalytic amount of an acid such as p-TsOH, in a suitable solvent such as THF provides Ic (R₆ and R₇ are not H). When R₄ = H, the use of an aldehyde (R₅CHO) instead of a ketone provides Id. This compound may be oxidized to Ib by treatment with a suitable oxidizing agent such as MnO₂ or dichlorodicyanobenzoquinone.

10

Compounds of formula (Ib) where R₅ = NHR₉, represented by formula (Ib') below, may be prepared from intermediate XIX (where R₄ = H) by Method H as illustrated in Scheme 8.


Scheme 8 (Method H)



Reaction of XIX with an isothiocyanate in a suitable solvent such as DMF or THF provides thiourea XXII. Cyclization of XXII may be accomplished by the addition of a suitable condensing agent such as mercury oxide to produce the desired product of formula (Ib').

Scheme 9 (Method I) illustrates a procedure by which compounds of formula (I) with X = S may be prepared. Intermediate XXV may be prepared from XXIII by reaction with an acid chloride (R₅C(O)Cl) to form an intermediate amide, followed by cyclization by treating with a suitable base such as sodium methoxide. Alternatively, if R₅ = H one may react XXIV with triazine in a suitable solvent such as EtOH, in the presence of a suitable base such as piperidine to produce XXV (R₅=H). Reduction of the nitro group to give XXVI and formation of thiourea XXVII may be accomplished by procedures described in the above Methods. Cyclization of XXVII to give I (X = S) may be achieved by treatment with bromine in a suitable solvent such as CHCl₃.

Scheme 9 (Method I)



Several of these transformations are also exemplified below.

5

Methods of Therapeutic Use

The compounds of the invention are useful in inhibiting the activity of src-family kinases and PDGFR kinase. In doing so, the compounds are effective in blocking disease processes mediated by these kinases. For example, by inhibiting p56 lck, the compounds block downstream signaling events following T cell activation by antigen. Activation of antigen-specific T cells is necessary for the induction and progression of diseases, including autoimmune diseases, allergic diseases and transplant rejection (J.H. Hanke et al., *Inflamm. Res.*, 1995, 44, 357). Therefore the compounds of the invention are useful for treating such diseases. These include but are not limited to rheumatoid arthritis, multiple sclerosis,

10

15

Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.

In view of their inhibitory effect on src-family kinases and PDGFR kinase, the compound
5 of the invention are useful in treating cancer. For example, the compounds of the
invention are useful in treating src-dependent tumors, such as in mammary carcinoma,
colon carcinoma, melanoma and sarcoma, and are also useful in treating PDGF-dependent
tumors, such as ovarian cancer, prostate cancer and glioblastoma. . In view of their
inhibitory effect on src kinase, the compounds of the invention are also useful in treating
10 conditions involving cerebral ischemia, for example, in reducing brain damage following a
stroke.

By inhibiting p60src, compounds of the invention may also be useful in treating
15 osteoporosis, Paget's disease, bone inflammation and joint inflammation . By inhibiting
PDGFR kinase, compounds of the invention may also be useful in treating fibrotic
diseases, restenosis and atherosclerosis. By inhibiting lyn kinase, the compounds of the
invention may also be useful in enhancing or potentiating the effectiveness of radiation
therapy.

20
For therapeutic use, the compounds of the invention may be administered in any
conventional dosage form in any conventional manner. Routes of administration include,
but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by
infusion, sublingually, transdermally, orally, rectally, topically or by inhalation. The
25 preferred modes of administration are oral and intravenous. Compositions comprising the
compounds of the invention for each of the aforementioned routes of administration will be
apparent to the skilled artisan. For example, one embodiment of the invention provides for
pharmaceutical compositions including a therapeutically effective amount of the
compounds according to the invention. Such pharmaceutical compositions will include
30 pharmaceutically acceptable carriers and adjuvants as further described below.

The compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including
5 other active ingredients. Advantageously, such combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. Compounds of the invention may be physically combined with the conventional therapeutics or other adjuvants into a single pharmaceutical composition. Advantageously, the compounds may
10 then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions comprising such combinations of compounds contain at least about 5%, but more preferably at least about 20%, of a compound of formula (I) (w/w) or a combination thereof. The optimum percentage (w/w) of a compound of formula (I) may vary and is within the purview of those skilled in the art. Alternatively, the compounds
15 may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.

As mentioned above, dosage forms of the compounds of this invention include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the
20 art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule, suppository and transdermal patch. Methods for preparing such dosage forms are known
25 (see, for example, H.C. Ansel and N.G. Popovich, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 1-1000 mg/dose for a 70 kg patient. Although one dose
30 per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may


be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition thereto, and the judgment of the treating physician.

5

Synthetic Examples

Example 1: Synthesis of 2-(2,6-Dichlorophenylamino)-1*H*-imidazo[4,5-*f*]quinazoline-7,9(6*H*,8*H*)-dione.

10



To a solution of 6-chloroanthranilic acid (1.72 g, 10 mmol) and NaOH (0.40 g, 10 mmol) in water (15 mL) was added sodium cyanate (0.72 g, 11 mmol), followed by acetic acid (0.66 g, 11 mmol). The solution was stirred for 9 h, and then acidified with conc. HCl. The precipitate was filtered off and washed with water. The wet solid was added to a

15

solution of NaOH (8.0 g, 200 mmol) in water (60 mL) and stirred for 20 h. The precipitate was filtered off and suspended in water (80 mL), then heated to boiling and acidified with 50% H₂SO₄. The cooled mixture was filtered, the solid washed well with water and dried to give 5-chloroquinazolin-2,4-dione (1.42 g, 72%).

5

A solution of the above quinazolinedione (0.98 g, 5.0 mmol) in conc. H₂SO₄ (5 mL) was cooled to -10 °C, and 90% HNO₃ (0.35 g, 5.0 mmol) was added with stirring. Stirring continued for 1 h at -10 °C, and 1.5 h at room temperature. The mixture was poured onto ice, filtered, washed with water and dried to give 5-chloro-6-nitroquinazolin-2,4-dione, along with some of the 8-nitro isomer (1.3g, 94%).

10

Butanol (10 mL) was saturated with ammonia and placed in a sealed tube with the above compound (1.0 g, 4.1 mmol). The tube was heated to 125 °C for 3 h, then cooled. The solid was collected, washed with water, then ether, and dried to give 5-amino-6-nitroquinazolin-2,4-dione (0.82 g, 89%).

15


A suspension of the above amine (450 mg, 2.0 mmol) in DMF (15 mL) was hydrogenated over 10% Pd/C (60 mg) at 50 psi for 20 h. The catalyst was removed by filtration and the solvent removed to give 5,6-diaminoquinazolin-2,4-dione (369 mg, 95%) as a dark solid.

20

A mixture of the above diamine (342 mg, 1.78 mmol) and 2,6-dichlorophenyl-isothiocyanate (400 mg, 1.96 mmol) in DMF was stirred for 17 h. The solvent was removed and the residue triturated with EtOAc to give the thiourea. A portion of the thiourea (200 mg, 0.51 mmol) was dissolved in DMF (2 mL) and a solution of dicyclohexylcarbodiimide (125 mg, 0.61 mmol) in THF (4 mL) was added. The mixture was heated to 80 °C under reflux for 7 h, and the solvent removed. The residue was dissolved in CH₂Cl₂/THF/TFA (150:50:1) and filtered through a plug of silica. The filtrate was evaporated, the residue triturated twice with THF, and the supernatant pipetted off. The solid was suspended in MeOH, neutralized with NH₄OH, and the product collected by centrifugation to give the title compound, 1 (89mg). Mp >300 °C.

30

Example 2: Synthesis of 2-(2,6-Dichlorophenylamino)-6-methyl-1*H*-imidazo[4,5-*f*]quinazoline-7,9(6*H*,8*H*)-dione.



5

Sodium (3.35 g, 146 mmol) was slowly added to stirred MeOH (45 mL). Upon completion of gas evolution, 6-chloroanthranilic acid (5 g, 29 mmol) was added forming a suspension. This mixture was added to a separate flask containing a suspension of paraformaldehyde (1.22 g, 43.5 mmol) in MeOH (35 mL), and the resulting solution was stirred for 5 h at
10 room temperature. Sodium borohydride (1.1g, 29 mmol) was added and the mixture refluxed for 3h. The cooled mixture was hydrolyzed with 1 M potassium hydroxide then neutralized to pH 3 using 2 M HCl. The precipitate was filtered to yield 2-chloro-6-methylamino benzoic acid (2.2 g, 41%).


15 2-Chloro-6-methylamino benzoic acid was converted to 5-amino-1-methyl-6-nitroquinazolin-2,4-dione by the three step procedure described in Example 1.

A suspension of 5-amino-1-methyl-6-nitroquinazolin-2,4-dione (400 mg, 1.64 mmol) in MeOH (70 mL) was hydrogenated over 10% Pd/C (150mg) in a Parr shaker at 50 psi until
20 uptake ceased. The catalyst was removed by filtration and the filtrate concentrated to yield 5,6-diamino-1-methylquinazolin-2,4-dione (350 mg, 99% crude).

A solution of the above diamine (350 mg, 1.69 mmol) and 2,6-dichlorophenylisothiocyanate (381 mg, 1.88 mmol) in DMF (15 mL) was stirred under
25 nitrogen for 72 hr. The solvent was evaporated and the residue triturated with ethyl acetate to yield the thiourea (430 mg, 62%). A portion of the thiourea (300 mg, 0.73 mmol) was dissolved in DMF (3 mL) and a solution of dicyclohexylcarbodiimide (166 mg, 0.8 mmol)

in THF (6 mL) was added. The mixture was stirred at 80 °C for 4 h. The solvent was removed, and the residue crystallized twice from MeOH to yield the title compound, 2 (65mg, 24%). Mp >300 °C.

5 **Example 3: Synthesis of 2-(2,6-Dichlorophenylamino)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one.**



10 A solution of 6-chloro anthranilic acid (2.12 g, 12.3 mmol) and triazine (1.0 g, 12.3 mmol) in EtOH (40 mL) containing piperidine (3 drops) was heated under reflux with stirring for 8 h. On cooling crystals formed, which were filtered to yield 5-chloroquinazolin-4-one (1.55 g, 70%).

15 A solution of the above quinazolinone (1.26 g, 7.0 mmol) in conc. H₂SO₄ (7 mL) was cooled to -20 °C, and 90% HNO₃ (0.49 g, 7.0 mmol) was added with stirring. Stirring continued for 1 h at -20 °C, and 2 h at room temperature. The mixture was poured onto ice, filtered, washed with water and dried to give 5-chloro-6-nitroquinazolin-4-one,


along with the 8-nitro isomer in a 4:1 ratio. Three recrystallizations from EtOH gave the product as a 6:1 ratio of isomers (0.85g).

Butanol (20 mL) was saturated with ammonia and placed in a sealed tube with the above
5 compound (800 mg, 3.6 mmol). The tube was heated to 125 °C for 14 h, then cooled. The solid was collected, washed with EtOH and water, and dried to give 5-amino-6-nitroquinazolin-4-one (569 mg, 78%).

A suspension of the above amine (250 mg, 1.21 mmol) in MeOH (50 mL) was
10 hydrogenated over 10% Pd/C (50 mg) at 50 psi for 5 h. The catalyst was removed by filtration and the filtrate concentrated to yield 5,6-diaminoquinazolin-4-one (210 mg, 98% crude).

A solution of the above diamine (205 mg, 1.19 mmol) and 2,6-
15 dichlorophenylisothiocyanate (272 mg, 1.3 mmol) in DMF (3 mL) was stirred under nitrogen for 18 h. The solvent was evaporated and the residue triturated with ethyl acetate to yield the thiourea (350 mg, 77%). The thiourea was dissolved in DMF (4 mL) and a solution of dicyclohexylcarbodiimide (228 mg, 1.1 mmol) in THF (8 mL) was added. The mixture was stirred at 80 °C for 8 h and the solvent evaporated. The residue was purified
20 by column chromatography in CH₂Cl₂/MeOH 98:2 – 90:10. Pure fractions were combined, evaporated, and the residue recrystallized from MeOH to give the title compound, 3 (87 mg). mp 230-235 °C.

25 **Example 4: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one.**



5 5-Chloro-6-nitroquinazolin-4-one, from Example 3 (0.26 g, 1.15 mmol) was suspended in MeOH (3 mL) at -20°C . Methylamine gas was passed into the mixture for a few minutes, resulting in a clear solution. The solution was stirred at room temperature for 5 h and evaporated to give 5-methylamino-6-nitroquinazolin-4-one in quantitative yield.


The above amine (350 mg, 1.6 mmol) was hydrogenated over platinum oxide (30 mg) in MeOH (200 mL) at 60 psi for 4 h. The mixture was filtered through diatomaceous earth and the solvent evaporated, to give 6-amino-5-methylaminoquinazolin-4-one, which was
10 immediately suspended in EtOAc (20 mL) and THF (10 mL). A solution of 2,6-dichlorophenylisothiocyanate (340 mg, 1.67 mmol) in EtOAc (5 mL) was added, and the mixture stirred for 16 h. The reaction mixture was concentrated to half the volume, filtered, and the solid washed with EtOAc to yield the thiourea (400 mg, 64% over 2 steps.)

15 A solution of the above thiourea (295 mg, 0.75 mmol) and dicyclohexylcarbodiimide (160 mg, 0.78 mmol) in THF (12 mL) and DMF (10 mL) was heated to 70°C with stirring for 48 h. The mixture was poured into ice water (50 mL) and filtered. The filtrate was extracted with EtOAc and evaporated. The residue was combined with the filtered solid,
20 triturated with chloroform, and the supernatant decanted. The solid was dissolved in boiling MeOH (100 mL), filtered hot, concentrated to 60 mL, and water (10 mL) added slowly. The crystals were collected to give the title compound, 4 (110 mg, 41%). Mp $>300^{\circ}\text{C}$.

25 **Example 5: Synthesis of 2-(2,6-Dichlorophenylamino)-1-ethyl-1,8-dihydro-9H-imidazo[4,5-f]quinazolin-9-one.**

This compound was synthesized in by the method of Example 4. Mp >300 °C.

Examples 6 and 7



5

Example 6; Synthesis of 2-(2,6-Dichlorophenylamino)-1,7-dimethyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one.

A solution of 2,6-dichloro-3-nitrobenzonitrile (98.7 g, 0.455 mol) in EtOAc (910 mL) was cooled to 5°C. 40% Aqueous methylamine (79.5 mL, 1.14 mol) was added with vigorous mechanical stirring, keeping the temperature at 10-15°C. After addition was complete, stirring was continued for 3 h at the same temperature. More methylamine (16 mL, 0.23 mol) was added, and the mixture stirred for a further 1.5 h at room temperature. Water (300 mL) was added, followed by hexane (450 mL). The mixture was stirred for 15 min, filtered, and the solid washed with water and MeOH, to give 6-chloro-2-methylamino-3-nitrobenzonitrile (80.3 g, 83%), mp 167-170°C.

10

A suspension of the above amine (30.0 g, 142 mmol) in a 5.3 M solution of ammonia in ethanol (200 mL) was heated in a sealed stainless steel reaction vessel (600 mL capacity) at 90 °C for 24 h. The reaction vessel was cooled to room temperature, then to 0°C, and opened. The product was filtered, washed with ethanol (30 mL) and dried to give 6-amino-2-methylamino-3-nitro-benzonitrile (25.94 g, 95%) as a yellow solid.

15

A solution of the above diamine (5.0 g, 26 mmol) in THF (150 mL) was hydrogenated over 10% Pd/C (1.0g) at 50 psi for 4 h. The reaction mixture was filtered through a pad of diatomaceous earth and rinsed with THF (50 mL). The filtrate was not concentrated but used crude as a THF solution.

20

To the above triamine solution was added 2,6-dichlorophenylisothiocyanate (5.3 g, 26 mmol) and the solution was stirred at room temperature for 0.5 hr. TLC indicated complete formation of the thiourea intermediate. Mercury (II) oxide (6.2 g, 29 mmol) was then added, and the mixture was heated to reflux for 2h. TLC showed conversion to the benzimidazole. The reaction mixture was cooled to room temperature, activated carbon (about 1g) was added, and stirred at 50 °C for 2h. The mixture was filtered through a pad of diatomaceous earth and rinsed with EtOAc until the filtrate was colorless. The combined filtrates were concentrated to obtain a pink solid, which was triturated with EtOAc/hexane (1:4). The light grey color solid was filtered and dried to give 5-amino-3-methyl-2-(2,6-dichlorophenylamino)-3H-benzimidazole-4-carbonitrile (7.42 g). The mother liquor was

30

concentrated and triturated again to provide a second crop (0.15 g), combined yield 87%, MS (EI^+): $\text{MH}^+ = 331$.

To the above amino nitrile (60 mg, 0.18 mmol) in THF (1 mL) was added acetic anhydride
5 (74 mg, 0.72 mmol) and DMAP (1 crystal), and the solution stirred for 22 h. MeOH (0.5 mL) was added, and stirring continued for 1 h. The solution was partitioned between EtOAc and dilute NH_4OH , and the residue from the organic layer purified by flash chromatography, eluting with $\text{CH}_2\text{Cl}_2/\text{THF}$ 95:5, to give recovered amino nitrile (18 mg) and 5-acetamido-3-methyl-2-(2,6-dichlorophenylamino)-3*H*-benzimidazole-4-carbonitrile
10 (47 mg).

A suspension of the above acetamide (30 mg, 0.08 mmol) in dioxan (1 mL) and 0.2M NaOH (1 mL) was heated to 110 °C. Urea-hydrogen peroxide complex (15 mg, 0.16 mmol) was added with stirring. Further 30 mg portions of urea-hydrogen peroxide were
15 added at 2.5 h, 3.5 h and 21 h. After heating for 25 h, the mixture was cooled and partitioned between THF and water. The residue from the organic layer was purified on a flash column, eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 98:2, to give the title compound, 6 (7 mg, 23%), mp 305-310 °C(dec), MS (ES) 374, 376 (MH^+).

20 **Example 7: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-phenyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one.**


A mixture of 5-amino-3-methyl-2-(2,6-dichlorophenylamino)-3*H*-benzimidazole-4-carbonitrile (Example 6) (1 g, 3 mmol) and conc. H_2SO_4 (8 mL) was warmed to 100-110
25 °C for 1 h and monitored by TLC for the disappearance of starting material. The mixture was cooled and poured onto a mixture of crushed ice, sodium carbonate, and ether. The precipitate was filtered, washed with water, dissolved in MeOH-methylene chloride, treated with carbon (decolorizing charcoal), dried (MgSO_4), filtered, and concentrated in vacuo. The aqueous filtrate was washed with EtOAc (3 x 30 mL). The combined organic
30 layers were washed with brine (25 mL), which was then extracted with EtOAc (20mL). The combined organic layers were dried (MgSO_4), filtered, and concentrated to yield 190

mg of a crude product. This was combined with the solid product and triturated with ether-methylene chloride to afford 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3*H*-benzoimidazole-4-carboxylic acid amide (700 mg, 66%). The filtrate was chromatographed on silica gel to afford an additional 128 mg (12%) of product.

5

The above amino amide (50 mg, 0.15 mmol) was added to a solution of benzoyl chloride (32 mg, 0.23 mmol) in THF (1 mL). Triethylamine (0.03 mL, 0.23 mmol) was added and the mixture stirred for 1 h. TLC showed conversion to the benzamide. The solvent was evaporated and the residue dissolved in MeOH (1 mL). Sodium methoxide in MeOH
10 (25%, 0.2 mL) was added and the solution heated to reflux for 45 min. The cooled mixture was partitioned between 1M NH₄Cl and CH₂Cl₂. The residue from the organic layer was stirred and refluxed with MeOH (2 mL) for 1 h, cooled, filtered and washed with MeOH to yield the title compound, 7 (52 mg, 79%) Mp >300 °C. MS (ES+) 436, 438 (MH⁺).

15 **Example 8: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-furan-3-yl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one.**




8

Furan-3-carboxylic acid (20 mg, 0.18 mmol), hydroxybenzotriazole (24 mg, 0.18 mmol)
20 and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (35 mg, 0.18 mmol) were stirred together in DMF (1 mL) for 15min. 5-Amino-2-(2,6-dichlorophenylamino)-3-methyl-3*H*-benzoimidazole-4-carboxylic acid amide (Example 7)(50 mg, 0.15 mmol) was added, and stirring continued for 24 h. The solution was diluted with EtOAc and washed in turn with aqueous Na₂CO₃, water and brine. The organic layer was evaporated and the
25 residue dissolved in MeOH (2 mL). Sodium methoxide in MeOH (25%, 0.1 mL) was added and the solution heated to reflux for 45 min. The cooled solution was partitioned

between water and CH_2Cl_2 . The organic layer was evaporated and the crude product stirred with MeOH (1 mL) for 1 h. The solid was filtered, washed with a few drops of MeOH and dried to yield the title compound, 8 (14 mg, 22%). mp $>300^\circ\text{C}$. MS (ES) 428, 426 (MH⁺).

5

Example 9: Synthesis of 7-allylamino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one.



9


10 A mixture of 100 mg (0.286 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7) and 114 mg (1.15 mmol) of allyl isothiocyanate in DMF was warmed at 45°C for 48 h. The reaction was diluted with 30 mL of brine and extracted with four 15 mL portions of EtOAc. The combined organic layers were washed with five 15 mL portions of brine, dried (MgSO_4), filtered and

15 concentrated in vacuo. The residue was adsorbed onto silica gel and chromatographed on silica gel (MeOH-methylene chloride, first 2:98, then 4:96, then 5:95) to afford 66 mg (51 %) of 2-(2,6-dichlorophenylamino)-3-methyl-5-(3-allyl-thioureido)-3H-benzimidazole-4-carboxylic acid amide.

20 A mixture of 66 mg (0.15 mmol) of the above amide and 300 mg (1.38 mmol) of mercury (II) oxide in THF was warmed at reflux for 18 h. The reaction was cooled to room


temperature and filtered through diatomaceous earth. The filtrate was adsorbed onto silica gel and chromatographed over silica gel (methylene chloride, then MeOH-methylene chloride, first 1:99, then 2:98, then 3:97) to afford an off white solid which was triturated with methylene chloride-MeOH to afford 17 mg (27%) of the title compound 9, mp 255-260 °C.

Example 10: Synthesis of *N*-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazolin-7-yl]-benzamide.



To a solution of 128 mg (0.36 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3*H*-benzimidazole-4-carboxylic acid amide (Example 7) in 10 mL of THF was added 72 mg (0.45 mmol) of benzoyl isothiocyanate. The reaction was warmed at reflux and after 5 min, thin-layer chromatography indicated a new product. 95 mg (0.44 mmol) of mercury (II) oxide was added and refluxing continued for 24 h. The reaction was cooled and filtered through diatomaceous earth washing the filter cake with EtOAc. The crude residue was adsorbed onto silica gel and chromatographed over silica gel (MeOH-methylene chloride, first 1:99, then 2:98, then 3:97). The material from the column was triturated with ether-dichloromethane to afford 64 mg (36%) of the title compound 10, mp, 185-190 °C.


Example 11: Synthesis of 7-amino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazolin-9-one.



A mixture of 130 mg (0.27 mmol) 10 and 500 mg (3.62 mmol) of potassium carbonate in MeOH was stirred for 18 h. The mixture was then diluted with brine and extracted with EtOAc to afford 12 mg of product. Additional material was obtained as an insoluble solid from the extraction layers. The combined materials were dissolved in 1N aqueous HCl, diluted with THF, made basic with solid/saturated aqueous sodium bicarbonate and extracted with EtOAc to afford 40 mg (40%) of product. Trituration with ether gave 30 mg (30%) of title compound 11, mp > 305 °C.

10

Example 12: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-2-phenyl-vinyl)-1,6,7,8-tetrahydro-9H-imidazo[4,5-f]quinazolin-9-one.




15

A mixture of 110 mg (0.315 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide, 184 mg (1.26 mmol) of α -methyl-*trans*-cinnamaldehyde and 60 mg (0.31 mmol) of *p*-toluenesulfonic acid in 10 mL of THF were

stirred at RT for 18 h. The reaction was made basic with saturated aqueous sodium bicarbonate and extracted with EtOAc. The combined organic layers were washed with saturated aqueous sodium bicarbonate, brine, dried (MgSO₄), filtered and evaporated in vacuo. The crude residue was chromatographed on silica gel to afford 102 mg (68%) of title compound 12.

Example 13: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-2-phenyl-vinyl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one.




10

A mixture of 102 mg (0.213 mmol) 12 and 300 mg (3.45 mmol) of manganese dioxide was stirred in 15 mL of THF for 45 min. The reaction was filtered through diatomaceous earth and evaporated in vacuo. The crude residue was evaporated onto silica gel and chromatographed over silica gel (methylene chloride, then MeOH-methylene chloride first 1:99 then 2:98). The material from the column was triturated with MeOH-methylene chloride to afford 70 mg (69%) of title compound 13, mp > 305 °C.

15

Example 14: Synthesis of 2-(2,6-Dichlorophenylamino)-1-methyl-1H-imidazo[4,5-f]quinazoline-7,9(6H,8H)-dione.




20

To a solution of 80 mg (0.229 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7) in 8 mL THF cooled to 0 °C was added 67 mg (0.23 mmol) of triphosgene. After stirring 30 min, the reaction was diluted with saturated aqueous sodium bicarbonate and water, and the THF was evaporated in vacuo. The resulting suspension was filtered and the solid dried by pulling vacuum through the filter cake. The crude product was absorbed onto silica gel and chromatographed over silica gel (MeOH-methylene chloride first 1:99 then 2:98 then 3:97 then 4:96) to afford a solid which was triturated with methylene chloride to afford 20 mg (23%) of the title compound 14, mp > 300 °C.

10


Example 15: Synthesis of 2-(2,6-Dichlorophenylamino)-1,7-dimethyl-1,6,7,8-tetrahydro-9H-imidazo[4,5-f]quinazolin-9-one.



15 A mixture of 30 mg (0.086 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7) and 1 mL (18 mmol) of acetaldehyde was stirred under an argon atmosphere while chilled in an ice-water bath for 0.5 h, then warmed to room temperature. *p*-Toluenesulfonic acid was added, (catalytic) and after stirring for 1 h, 2 mL of MeOH was added. After 2 h the reaction was poured into a mixture of saturated aqueous sodium bicarbonate and EtOAc. The aqueous layer was extracted with EtOAc, the combined organic layers were extracted with saturated aqueous sodium bicarbonate, brine, dried (MgSO₄), treated with activated carbon, filtered, and concentrated in vacuo. The residue was chromatographed over silica gel, followed by elution on a TLC plate to yield 11 mg (34%) of title compound 15, mp 200-203 °C.


25

Example 16: Synthesis of 2-(2,6-Dichlorophenylamino)-1,7,7-trimethyl-1,6,7,8-tetrahydro-9H-imidazo[4,5-f]quinazolin-9-one.



- 5 A mixture of 38 mg (0.11 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7), 3 mg (0.02 mmol) *p*-toluenesulfonic acid, and 2 mL (27 mmol) of acetone was stirred at room temperature for 1 h, then heated to reflux for 1.5 h. The reaction was cooled and poured into a mixture of saturated aqueous sodium bicarbonate and EtOAc. The aqueous phase was extracted with EtOAc,
- 10 the combined organics were extracted with saturated aqueous sodium bicarbonate, brine, dried (MgSO₄), treated with activated carbon, filtered, and concentrated in vacuo to afford 26 mg of an orange solid. The crude product was chromatographed over silica gel to afford 20 mg (47%) of title compound 17, mp 238-239 °C.

- 15 **Example 17: Synthesis of 2-(2,6-Dichlorophenylamino)-1,7-dimethyl-9-oxo-6,7,8,9-tetrahydro-1H-imidazo[4,5-f]quinazoline-7-carboxylic acid ethyl ester.**







- A mixture of 100 mg (0.29 mmol) of 5-amino-2-(2,6-dichlorophenylamino)-3-methyl-3H-benzimidazole-4-carboxylic acid amide (Example 7), 332 mg (2.9 mmol) of ethyl
- 20




pyruvate, and a catalytic amount of *p*-toluenesulfonic acid in 2 mL of dichloromethane was heated in a sealed tube to 85 °C for 2 h, then 0.5 mL EtOH was added, and heating continued for 15 min. The reaction was cooled and stirred at room temperature for 1 h. The reaction was concentrated in vacuo, and the residue was suspended in dilute aqueous sodium hydroxide, filtered, washed with water and dried by pulling vacuum through the filter cake. The crude product was purified on a TLC plate, and recrystallized from EtOAc to afford 17.6 mg (13.5%) of title compound 17, mp 245-247 °C.

Additional Examples





- 10 The following additional compounds (Ex. Nos. 18 to 104) in the following Table were prepared by methods analogous to those described above.





Ex. No.	Structure	M. P.(°C)
18		>300
19		200 (dec)





20	 <chem>CCNC(=O)Nc1ccc(cc1)Nc2nc3c(cc2)nc(Nc4cc(Cl)cc(Cl)c4)n(C)c3</chem>	251 (dec)
21	 <chem>C=CC1=NC2=C(N1)C(=O)Nc3nc(Nc4cc(Cl)cc(Cl)c4)c5ccccc35</chem>	278- 284 (dec)
22	 <chem>Cc1nc2c(cc1)nc(Nc3cc(Cl)cc(Cl)c3)c4ccccc24</chem>	>300
23	 <chem>Cc1nc2c(cc1)nc(Nc3cc(Cl)cc(Cl)c3)c4cc5c(cc2)sc(S(=O)(=O)C)c(Cl)c5</chem>	280





24	 <chem>CN1C=NC2=C(C1=NC(=C3C(=C(C=C3)N=C(C=C2)N4C(=CS4)C5=CC=CC=C5[N+](=O)[O-])C5=CC=CC=C5)C(=O)N2)NC6=CC(=CC=C6)Cl</chem>	>300
25	 <chem>CN1C=NC2=C(C1=NC(=C3C(=C(C=C3)N=C(C=C2)N4C(=CN4)C5=CC=CC=C5)C(=O)N2)NC6=CC(=CC=C6)Cl</chem>	>300
26	 <chem>CN1C=NC2=C(C1=NC(=C3C(=C(C=C3)N=C(C=C2)N4C(=CO4)C5=CC=CC=C5)C(=O)N2)NC6=CC(=CC=C6)Cl</chem>	>290






27		>300
28		>300
29		>300
30		>300
31		185-192





32		>300
33		>300
34		>250 (dec)
35		295 (dec)





36		240 (dec)
37		275-277
38		>300
39		>300




40		258 (dec)
41		265-268
42		>300
43		>300

44		
45		278 (dec)
46		>300
47		>300



48		173-174
49		279 (dec)
50		283-284
51		
52		295 (dec)




53		>300
54		255
55		289-292
56		>300




57		280-283
58		304-310 (dec)
59		>300
60		280 (dec)

61		215 (dec)
62		198-204
63		>300





64	<chem>CCCCCCCc1nc2c(c1)c(=O)[nH]2n3c4cc(Cl)c(Cl)cc4n3C</chem>	257-260
65	<chem>CC(C)(C)OC(=O)N1CCN(CC1)CN2C=C(C2)C3=C4C(=C5C(=CC(=C5)C(=O)N4C3N5C6=CC(Cl)=CC(Cl)=C6)N4)N</chem>	168-170
66	<chem>O=C1C(=C2C(=CC(=C2)C(=O)N1C3=CC(Cl)=CC(Cl)=C3)N2)C4=CC(O)C=C4</chem>	285




67	 <p>Chemical structure of compound 189: A benzimidazole core substituted with a 4-phenylphenyl group at position 2, a 2,6-dichlorophenyl group at position 4, and a methyl group at position 5. The benzimidazole ring is further substituted with a piperidine ring via a sulfonamide group at position 7. The piperidine ring is also substituted with a tert-butyl ester group at position 4.</p>	189
68	 <p>Chemical structure of compound 210: A benzimidazole core substituted with a 4-phenylphenyl group at position 2, a 2,6-dichlorophenyl group at position 4, and a methyl group at position 5. The benzimidazole ring is further substituted with a piperidine ring via a sulfonamide group at position 7. The piperidine ring is also substituted with a hydrogen atom at position 4.</p>	210





69		>295 (dec)
70		288-290
71		290-292




72		>215 (dec)
73		209
74		254-256




75		163-169
76		155-160
77		295-300 (dec)
78		161-166




79		295 (dec)
80		310-313
81		>300
82		>275 (dec)




83		206-208
84		>300 (dec)
85		246 (dec)




86		240-241 (dec)
87		126-128
88		228-230
89		197-205

90	 <chem>NC(=N)Nc1ccc(S(=O)(=O)N2CCCN(C2)c3ccccc3c4c5c6ccccc6n5c7c8ccccc8n7C)c4=O</chem>	215
91	 <chem>OCc1ccccc1S(=O)(=O)N2CCCN(C2)c3ccccc3c4c5c6ccccc6n5c7c8ccccc8n7C)c4=O</chem>	>300
92	 <chem>NC(=N)Nc1ccc(C=Cc2ccccc2C(=O)c3c4c5c6ccccc6n5c7c8ccccc8n7C)c3=O</chem>	>300

93		>300
94		210-215
95		265 (dec)

96		190
97		315-317 (dec)
98		290 (dec)

99		195-200 (dec)
100		246
101		170 (dec)

102		284-288
103		>300
104		

Assessment of Biological Properties

Tyrosine Kinase Inhibition Assay

- 5 The inhibition of tyrosine kinases by the compounds of the invention was measured with the following assay.

Kinase Reaction Buffer 50mM Hepes, pH 7.5, 50mM KCl, 25mM MgCl₂, 5mM MnCl₂,
10 100 μ M, Na₃VO₄, .01% CHAPS, 1mM DTT, and 50mg/mL BSA, Adenosine 5'-
Triphosphate (ATP) solution at 100mM, pH 7.5 - γ 33P-ATP, 2000 Ci/mmol at 10 μ Ci/ μ l, -
Poly(L-glutamic acid-L-tyrosine, 4:1) or (E4Y)_n at 10mg/mL in water.

Assay: Test compounds, obtained routinely at 5mg/mL in 100% DMSO were diluted
15 appropriately into complete Kinase assay buffer with 10% DMSO, 10 μ l of the 6X
compound solution was distributed into each assay well, the final compound concentration
for IC₅₀ determinations ranged from 200 to 1 μ g/mL. [γ 33P]-ATP label was prepared as a
10 Ci/mmol working solution in complete Kinase assay buffer. Protein kinase was
initiated by adding 10 to 50 η g of diluted enzyme stock.

20 Plates were incubated at 30 °C for 30 min. During the incubation period, the MultiScreen
harvest plates were pre-wetted with 10% TCA/5% Ppi. 150 μ l of TCA/PPi was added to all
MultiScreen plate wells after pre-wetting. The kinase reaction was stopped via replica
transfer of the polypropylene reaction wells into the MultiScreen plates. The plates were
25 incubated at room temperature for 5 min then vacuum harvested and washed with 200 μ l
TCA/PPi 3-4 times per well, then 100 μ l of cocktail per well was added.

Experimental data consisted of eight (8) compound doses in duplicate with ten (10)
enzyme control reaction wells (so-called totals) and six (6) background wells. The results

are presented as Percent Inhibition (Mean with S.D.) over the full compound dose range. IC₅₀ potency estimates are determined using a floating inhibition maximum (Imax).

All compounds in the synthetic examples and Tables above were evaluated in the tyrosine
5 kinase assay above using p56 lck and were found to have IC₅₀'s less than 10 µM.

Representative compounds from the examples above were evaluated in the tyrosine kinase assay above using p60 src and were found to have IC₅₀'s less than 10 µM.

10 Representative compounds from the examples above were evaluated in the tyrosine kinase assay above using PDGFR kinase and were found to have IC₅₀'s less than 10 µM.

Inhibition of IL-2 Production

15 Inactivation of T cells resulting from inhibition of the tyrosine kinase p56 lck can be measured by inhibition of IL-2 production in Jurkat cells. 96-well flat bottom plates were coated with anti-CD3, clone UCHT1, (Immunotech cat. # 1304) at 4 µg/ml in Phosphate Buffered Saline (PBS), 100 µl/well. The solution was prepared by taking 200 µl of 200 µg/ml anti-CD3 stock/ 10ml PBS. The plate was then incubated at 37°C for 2h. Jurkat
20 cells were pelleted and counted. The cells were resuspended at 2.5×10^6 cells/ml in RPMI, 10 % FBS (complete media). Test compounds were diluted from a 5mg/ml DMSO stock directly into complete media.

10 µl of 20 X compound/ well was added to a separate plate, followed by 100µl of cell suspension in triplicate and this plate was preincubated at 37°C for 30min. The 96-well
25 plate containing anti-CD3 was aspirated, and the cells and compound transferred to this plate. 100 µl of PMA (Phorbol 12-Myristate 13-Acetate, Sigma cat.# P-8139) at 20 ng/ml was added, and the plate was incubated overnight at 37° C. (PMA stock at 1 mg/ml in ethanol, dilute 10 µl/ml in complete media, then 20 µl/10 mls. in complete media. 100 µl/well = 10 ng/ml. final concentration). The next day, the plate was centrifuged at 1500
30 rpm for 5 min. at room temperature and the supernatants were removed. The supernatants were tested using R&D Systems Quantikine Human IL-2 Kit (cat.#2050). Samples were


diluted 1:5 in RPMI1640, and 100 μ l/well used in the ELISA. The optical density of each well was determined using a microplate reader set to 450 nm. EC₅₀ values were determined using Origin (non-linear regression) or SAS by plotting absorbance vs. concentration of compound.

5

Representatives from the synthetic examples and the Tables above were screened in this assay and had IC₅₀'s below 10 μ M.

We claim:

1. A compound of the following formula (I):



(I)

10 wherein:

Ar₁ is an aromatic or nonaromatic carbocycle, heteroaryl or heterocycle; wherein said
 15 carbocycle, heteroaryl or heterocycle is optionally substituted by one or more R₁, R₂ and R₃;

X is NH, N-C₁₋₃alkyl, N-cyclopropyl, S or O;

20 Y is NR₁₃;


R₁ and R₂ are the same or different and are selected from H, halogen, CN, NO₂, C₁₋₁₀
 branched or unbranched saturated or unsaturated alkyl, C₁₋₁₀ branched or unbranched
 alkoxy, C₁₋₁₀ branched or unbranched acyl, C₁₋₁₀ branched or unbranched acyloxy, C₁₋₁₀
 25 branched or unbranched alkylthio, aminosulfonyl, di-(C₁₋₃)alkylaminosulfonyl, NR₈R₉,
 aryl, aroyl, aryloxy, arylsulfonyl, heteroaryl and heteroaryloxy; wherein the
 abovementioned R₁ and R₂ are optionally partially or fully halogenated or optionally
 substituted with one to three groups independently selected from the group consisting of

oxo, OH, NR_8R_9 , C_{1-6} branched or unbranched alkyl, C_{3-7} -cycloalkyl, phenyl, naphthyl, heteroaryl, aminocarbonyl and mono- or di(C_{1-3})alkylaminocarbonyl;

R_3 is selected from the group consisting of H, halogen, OH, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$,

- 5 C_{1-3} alkyl optionally substituted with OH, C_{1-3} alkoxy optionally halogenated and C_{1-3} alkylthio;

Het represents a fused heterocyclic ring having a formula A, B or C:



10

R_4 is selected from H, C_{1-6} alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C_{1-3} alkoxy, C_{3-10} -cycloalkyl, or C_{5-8} cycloalkenyl; or R_4 is selected from $(\text{CH}_2)_m\text{NR}_8\text{R}_9$, $(\text{CH}_2)_m\text{NR}_8\text{COR}_{10}$, $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$, $(\text{CH}_2)_n\text{CONR}_8\text{R}_9$,
 15 phenyl, heteroaryl or heterocycle, each phenyl, heteroaryl or heterocycle being optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, $(\text{CH}_2)_m\text{NR}_8\text{R}_9$, OH, SO_3H or halogen;

R_5 is selected from H, C_{1-10} alkyl branched or unbranched, C_{3-10} cycloalkyl, C_{5-7} cycloalkenyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} acyl, each being optionally substituted with
 20 one or more halogen, OH, oxo, CN, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-3} alkoxy, NR_8R_9 , ureido, guanidino, $\text{NR}_8\text{COR}_{10}$, SR_{10} , CONR_8R_9 , CO_2R_{10} , C_{3-10} cycloalkyl, C_{3-10} cycloalkylidene, C_{5-7} cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle; wherein each of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkylidene, C_{5-7} cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted
 25 with one or more C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CN, NO_2 , amidino, guanidino, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; wherein one or more of the amino nitrogens in the

ureido, amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

or R₅ is selected from CO₂R₁₀, NR₈R₉, CONR₈R₉, aryl, heteroaryl, heterocycle, aryl-CO-,
 5 heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

C₁₋₃alkoxy, halogen, NO₂, CN, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀,
 (CH₂)_nCONR₈R₉, CO(CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉, ureido, guanidino, cycloalkyl, aryl,
 10 heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl optionally substituted with phenyl or NR₈R₉, wherein Z is a bridging group selected from C₁₋₁₀ alkylene branched or unbranched, CO, S(O)_p, O, S, NH, CONH, NHCO, COO or OOC, and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CO₂R₁₀, (CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉, ureido
 15 or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

20 or R₅ is a C₆₋₁₂ bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CO₂R₁₀, ureido, guanidino, amidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens
 25 in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy;

R₆ is selected from H, C₁₋₆alkyl branched or unbranched, C₂₋₆ alkenyl branched or unbranched, CO₂R₁₀, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl, arylC₁₋₃alkyl, heteroaryl and
 30 heterocyclyl; wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, aryl,

arylC₁₋₃alkyl, heteroaryl or heterocyclyl are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl, heteroaryl or heterocyclyl;

R₇ is H or C₁₋₆alkyl;

5

R₈ and R₉ are the same or different and are each independently selected from H, OH, CO₂R₁₀, C₁₋₁₀ acyl branched or unbranched, C₁₋₃alkoxy, C₁₋₆alkyl branched or unbranched, C₃₋₆alkenyl, C₃₋₈cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, aryl, arylC₁₋₃alkyl, aroyl, heteroaryl or heterocycle are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;

or R₈ and R₉ together form a 3-7 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, S(O)_p, NCOR₁₀, NCO₂R₁₀, NR₁₁ or NC(=NR₁₁)NR₁₁R₁₂; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;

R₁₀ is selected from H, C₁₋₆alkyl, C₃₋₈cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with phenyl, OH, C₁₋₃alkoxy, C₁₋₃alkanoyloxy or NR₁₁R₁₂, or R₁₀ is phenyl optionally substituted with one to three C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_mNR₈R₉, (CH₂)_nCONR₈R₉ or O(CH₂)₂₋₄NR₈R₉;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted with C₁₋₃alkoxy, OH or phenyl; or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or (CH₂)₂O(CH₂)₂;

R₁₃ is H or C₁₋₃alkyl;

P and Q are each independently CH or N;
m is 1-4;

n is 0-3;

and p is 0-2;

wherein one or more of the primary amine or secondary amine nitrogen atoms in any of the
5 R₄, R₅, R₆ and R₇ substituent groups may optionally be protected by a protecting group;

and the pharmaceutically acceptable derivatives thereof.

2. A compound according to claim 1 wherein:

10 Ar₁ is

a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;

b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;

15 c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl,

d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl,
20 benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl, or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline,
25 cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or

e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

5 wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;

R₁ and R₂ are as defined in claim 1, and R₃ is H, halogen, methyl, methoxy, hydroxymethyl or OH;

10 R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

R₅ is selected from H, C₁₋₁₀alkyl branched or unbranched, C₃₋₁₀cycloalkyl, C₅₋₇cycloalkenyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆acyl, each being optionally substituted with
 15 one or more halogen, OH, oxo, CN, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₃alkoxy, NR₈R₉, ureido, guanidino, NR₈COR₁₀, SR₁₀, CONR₈R₉, CO₂R₁₀, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylidene, C₅₋₇cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle; wherein each of C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylidene, C₅₋₇cycloalkenyl, aryloxy, arylthio, aryl, heteroaryl or heterocycle is optionally substituted
 20 with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the ureido, amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

25 or R₅ is selected from CO₂R₁₀, NR₈R₉, CONR₈R₉, aryl, heteroaryl, heterocycle, aryl-CO-, heteroaryl-CO- or heterocycle-CO-, wherein each aryl, heteroaryl or heterocycle is optionally substituted with one to three:

C₁₋₃alkoxy, halogen, NO₂, CN, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀,
 30 (CH₂)_nCONR₈R₉, CO(CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉, ureido, guanidino, cycloalkyl, aryl, heteroaryl, heterocycle, cycloalkyl-Z-, aryl-Z-, heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl

- optionally substituted with phenyl or NR_8R_9 , wherein Z is a bridging group selected from C_{1-10} alkylene branched or unbranched, CO , S(O)_p , O , S , NH , CONH , NHCO , COO or OOC , and wherein each cycloalkyl, aryl, heteroaryl or heterocycle is optionally substituted with NO_2 , C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$, ureido or guanidino, wherein one or more of the amino nitrogens in the ureido or guanidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;
- 10 or R_5 is a C_{6-12} bridged- or spiro-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 3 carbon atoms in the ring system may be replaced by heteroatoms selected from N, O and S; and wherein said ring system may be optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, halogen, CO_2R_{10} , ureido, guanidino, amidino, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; wherein one or more of the amino nitrogens in the ureido, guanidino or amidino groups in this paragraph may be optionally substituted with C_{1-3} alkyl, phenyl C_{0-3} alkyl or C_{1-3} alkoxy;
- 15 R_6 is selected from H, C_{1-6} alkyl branched or unbranched, C_{2-6} alkenyl branched or unbranched, or CO_2R_{10} ; wherein said C_{1-6} alkyl or C_{1-6} alkenyl are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $\text{NR}_{11}\text{R}_{12}$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_{11}\text{R}_{12}$, aryl, heteroaryl or heterocyclyl;
- R_7 is H or C_{1-6} alkyl;
- 25 R_8 and R_9 are the same or different and are each independently selected from H, OH, C_{1-3} alkyl branched or unbranched, CO_2R_{10} , C_{3-8} cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $\text{NR}_{11}\text{R}_{12}$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_{11}\text{R}_{12}$, aryl or heteroaryl;

30

- or R_8 and R_9 together form a 3-7 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by O, $S(O)_p$, $NCOR_{10}$, NCO_2R_{10} , NR_{11} or $NC(=NR_{11})NR_{11}R_{12}$; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, OH or $-(CH_2)_nNR_{11}R_{12}$;
- 5 R_{10} is H or C_{1-6} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy, C_{1-3} alkanoyloxy or $NR_{11}R_{12}$;
- R_{11} and R_{12} are each independently selected from H and C_{1-6} alkyl optionally substituted
- 10 with C_{1-3} alkoxy, OH or phenyl;
- or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$;
- 15 R_{13} is H; and

P and Q are each CH.

3. A compound according to claim 2 wherein:
- 20 Ar_1 is phenyl or pyridyl, each optionally substituted by one or more R_1 , R_2 and R_3 ;
- X is NH or N- C_{1-3} alkyl;
- 25 Y is NH;
- R_1 and R_2 are the same or different and selected from: halogen, C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally partially or fully halogenated, NO_2 or NR_8R_9 ;
- 30 R_3 is H, halogen, methyl or methoxy;

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉ or CO₂R₁₀;

R₅ is selected from H, C₁₋₃alkyl branched or unbranched, C₃₋₈ cycloalkyl,
 5 C₅₋₇cycloalkenyl or C₂₋₄ alkenyl, each being optionally substituted with one or more OH, CN, NR₈R₉, CONR₈R₉, C₃₋₈ cycloalkyl, C₅₋₇cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the amidino or
 10 guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

or R₅ is selected from CO₂R₁₀, NR₈R₉, CONR₈R₉, phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-
 15 pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

20 halogen, NO₂, S(O)_pNR₈R₉, C₀₋₃alkylS(O)_p, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or C₁₋₃alkyl optionally substituted with phenyl or NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched, O, S(O)_p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally
 25 substituted with NO₂, C₁₋₃alkyl, C₁₋₃alkoxy, CO₂R₁₀, (CH₂)_nNR₈R₉, O(CH₂)₂₋₄NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully
 30 halogenated;

or R_5 is a C_{6-7} bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with C_{1-3} alkyl, C_{1-3} alkoxy, halogen, $(CH_2)_nNR_8R_9$, or $O(CH_2)_{2-4}NR_8R_9$;

5

R_6 is selected from H, C_{1-6} alkyl branched or unbranched or CO_2R_{10} ;

R_7 is H or C_{1-6} alkyl;

10 R_8 and R_9 are the same or different and are each independently selected from H, C_{1-3} alkyl branched or unbranched, CO_2R_{10} , phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C_{1-3} alkoxy;

or R_8 and R_9 together form a $-(CH_2)_2-N(CO_2R_{10})-(CH_2)_2-$ group, a $-(CH_2)_2-$
15 $N(COR_{10})-(CH_2)_2-$ group, a $-(CH_2)_2-N(R_{11})-(CH_2)_2-$ group or a $-(CH_2)_2-$
 $N(C(=NR_{11})NR_{11}R_{12})-(CH_2)_2-$ group; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, or OH;

R_{10} is H or C_{1-6} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy,
20 C_{1-3} alkanoyloxy or $NR_{11}R_{12}$;

R_{11} and R_{12} are each independently selected from H and C_{1-3} alkyl optionally substituted with C_{1-3} alkoxy or OH;

25 or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$.

4. A compound according to claim 3 wherein:

30

Ar_1 is phenyl;

R₁ and R₂ are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, NO₂ and NH₂;

R₃ is H, chloro, fluoro, bromo or methoxy;

5

R₅ is selected from C₂₋₄ alkenyl, C₃₋₈ cycloalkyl or C₅₋₇cycloalkenyl, each being optionally substituted with one or more OH, CN, NR₈R₉, CONR₈R₉ or phenyl; wherein phenyl is optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens
10 in the amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy;

or R₅ is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-
15 cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

halogen, NO₂, SO₂NR₈R₉, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, cycloalkyl, phenyl,
20 heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C₁₋₃alkyl optionally substituted with NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched or S(O)_p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, CO₂R₁₀, NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may
25 be optionally substituted with C₁₋₃alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

or R₅ is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted
30 with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

R_6 is selected from H or C_{1-3} alkyl branched or unbranched,

R_7 is H or C_{1-3} alkyl;


- 5 R_8 and R_9 are the same or different and are each independently selected from H or C_{1-3} alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or C_{1-3} alkoxy;

or R_8 and R_9 together form a $-(CH_2)_2-N(CO_2R_{10})-(CH_2)_2-$, a $-(CH_2)_2-N(COR_{10})-(CH_2)_2-$ group, a $-(CH_2)_2-N(R_{11})-(CH_2)_2-$ group or a $-(CH_2)_2-N(C(=NR_{11})NR_{11}R_{12})-(CH_2)_2-$ group; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, or OH;

15 R_{10} is H or C_{1-3} alkyl optionally substituted with phenyl, OH or C_{1-3} alkanoyloxy; and

R_{11} is selected from H and C_{1-3} alkyl.


5. A compound according to any of claims 1, 2, 3 or 4, wherein the Het represents a
20 fused ring having formula B:



B

wherein R_5 is as defined in claims 1, 2, 3 or 4.

- 25 6. A compound according to claim 1, represented by the following formula (I'):



(I')

wherein R_1 , R_2 , R_3 , X , P , Q and Het are as defined in claim 1;

5 and the pharmaceutically acceptable derivatives thereof.

7. A compound according to claim 6 wherein:

X is NH or $N-C_{1-3}alkyl$;

10

R_1 and R_2 are the same or different and selected from: halogen, $C_{1-3} alkyl$,
wherein the $C_{1-3} alkyl$ is optionally partially or fully halogenated, NO_2 or NR_8R_9 ;

R_3 is H , halogen, methyl or methoxy;

15

R_4 is H , $C_{1-3}alkyl$ branched or unbranched, saturated or unsaturated, and optionally
substituted with OH ; or R_4 is $(CH_2)_{2-3}NR_8R_9$ or CO_2R_{10} ;

R_5 is selected from H , $C_{1-3}alkyl$ branched or unbranched, $C_{3-8} cycloalkyl$,
20 $C_{5-7}cycloalkenyl$ or $C_{2-4} alkenyl$, each being optionally substituted with one or more OH ,
 CN , NR_8R_9 , $CONR_8R_9$, $C_{3-8} cycloalkyl$, $C_{5-7}cycloalkenyl$, phenyl, heteroaryl or
heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with
one or more $C_{1-3}alkyl$, $C_{1-3}alkoxy$, halogen, CN , NO_2 , amidino, guanidino, $(CH_2)_nNR_8R_9$,
or $O(CH_2)_{2-4}NR_8R_9$; wherein one or more of the amino nitrogens in the amidino or
25 guanidino groups in this paragraph may be optionally substituted with $C_{1-3}alkyl$, phenyl,
 $C_{3-8}alkyl$, $C_{1-3}alkoxy$ or CO_2R_{10} ;

or R_5 is selected from CO_2R_{10} , NR_8R_9 , CONR_8R_9 , phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

halogen, NO_2 , $\text{S(O)}_p\text{NR}_8\text{R}_9$, $\text{C}_{0-3}\text{alkylS(O)}_p$, NR_8R_9 , $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or $\text{C}_{1-3}\text{alkyl}$ optionally substituted with phenyl or NR_8R_9 , wherein Z is a bridging group selected from C_{1-3} alkylene branched or unbranched, O, S(O)_p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO_2 , $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, CO_2R_{10} , $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, phenyl $\text{C}_{0-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxy}$; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R_5 is a C_{6-7} bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, halogen, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$;

R_6 is selected from H, $\text{C}_{1-6}\text{alkyl}$ branched or unbranched or CO_2R_{10} ;

R_7 is H or $\text{C}_{1-6}\text{alkyl}$;

R_8 and R_9 are the same or different and are each independently selected from H, $\text{C}_{1-3}\text{alkyl}$ branched or unbranched, CO_2R_{10} , phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or $\text{C}_{1-3}\text{alkoxy}$;

or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂- group, a -(CH₂)₂-N(COR₁₀)-(CH₂)₂- group, a - (CH₂)₂-N(R₁₁)-(CH₂)₂- group or a -(CH₂)₂-N(C(=NR₁₁)NR₁₁R₁₂)-(CH₂)₂- group; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, or OH;

5

R₁₀ is H or C₁₋₆alkyl optionally substituted with phenyl, OH, C₁₋₃alkoxy, C₁₋₃alkanoyloxy or NR₁₁R₁₂;

R₁₁ and R₁₂ are each independently selected from H and C₁₋₃ alkyl optionally substituted with C₁₋₃alkoxy or OH;

10

or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or (CH₂)₂O(CH₂)₂; and

15

P and Q are each CH.

8. A compound according to claim 7, wherein

R₁ and R₂ are the same or different and selected from: halogen, methyl optionally partially or fully halogenated, NO₂ and NH₂;

20

R₃ is H, chloro, fluoro, bromo or methoxy;

R₅ is selected from C₂₋₄ alkenyl, C₃₋₈ cycloalkyl or C₅₋₇cycloalkenyl, each being optionally substituted with one or more OH, CN, NR₈R₉, CONR₈R₉ or phenyl; wherein phenyl is optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenylC₀₋₃alkyl or C₁₋₃alkoxy;

25

or R₅ is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-

30

cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

- 5 halogen, NO₂, SO₂NR₈R₉, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C₁₋₃alkyl optionally substituted with NR₈R₉, wherein Z is a bridging group selected from C₁₋₃ alkylene branched or unbranched or S(O)_p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, CO₂R₁₀, NR₈R₉ or guanidino, 10 wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;

- or R₅ is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two 15 double bonds in the ring system, wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉;

R₆ is selected from H or C₁₋₃alkyl branched or unbranched;

- 20 R₇ is H or C₁₋₃alkyl;

R₈ and R₉ are the same or different and are each independently selected from H or C₁₋₃alkyl branched or unbranched; wherein said alkyl is optionally substituted with OH or C₁₋₃alkoxy;


- 25 or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂-, a -(CH₂)₂-N(COR₁₀)-(CH₂)₂- group, a -(CH₂)₂-N(R₁₁)-(CH₂)₂- group or a -(CH₂)₂-N(C(=NR₁₁)NR₁₁R₁₂)-(CH₂)₂- group; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, or OH;

30

R_{10} is H or C_{1-3} alkyl optionally substituted with phenyl, OH or C_{1-3} alkanoyloxy;
and

R_{11} is selected from H and C_{1-3} alkyl.

9. A compound according to any of claims 6, 7 or 8, wherein the Het represents a fused ring having formula B:




B

wherein R_5 is as defined in claims 6, 7 or 8.

10

10. A compound according to claim 1, represented by the following formula (Ib):



Ib

- wherein R is H, C_{1-3} alkyl or cyclopropyl, and Ar_1 and R_5 are as defined in claim 1;
and the pharmaceutically acceptable derivatives thereof.

11. A compound selected from the group consisting of:

2-(2,6-Dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

20

2-(2,6-Dichlorophenylamino)-7-furan-2-yl-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

- 2-(2,6-Dichlorophenylamino)-1-methyl-7-phenyl-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;
- 5 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-nitrophenyl)-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;
- 7-(3-Aminophenyl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;
- 10 1-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9*H*-imidazo[4,5-
f]quinazolin-7-yl]-phenyl}-3-ethylurea;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-vinyl-1,8-dihydro-9*H*-imidazo[4,5-
15 f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-thiophen-2-yl-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;
- 20 2-(2,6-Dichlorophenylamino)-1-methyl-7-[2-(3-nitrophenyl)-thiazol-4-yl]-1,8-dihydro-9*H*-
imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-7-imidazol-2-yl-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-
f]quinazoline-9-one;
- 25 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-phenyloxazol-5-yl)-1,8-dihydro-9*H*-
imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9*H*-imidazo[4,5-f]quinazoline-
30 7-carboxamide;

- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methylpropen-1-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-2-yl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-pyridin-3-yl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-1H-imidazo[4,5-f]quinazoline-7,9-6H,8H-dione;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-propen-2-yl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-Cyclopent-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-[2-(3-Aminophenyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- Ethyl 2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-7-carboxylate;
- 7-Benzofuran-2-yl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methylprop-1-enyl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methyloxazol-5-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;

- 2-(2,6-Dichlorophenylamino)-7-(1*H*-indole-3-carbonyl)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-piperazin-1-yl-cyclopent-1-enyl)-1,8-dihydro-
5 9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 7-Cyclohex-1-enyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 10 2-(2,6-Dichlorophenylamino)-1-methyl-7-(1-methyl-1,2,5,6-tetrahydro-pyridin-3-yl)-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[5-(2-nitrophenyl)-furan-2-yl]-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 15 2-(2,6-Dichlorophenylamino)-7-furan-3-yl-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 7-(5-Bromofuran-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 20 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-methylfuran-2-yl)-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 25 7-Cyclopropyl-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(4-methylpiperazine-1-sulfonyl)-phenyl]-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

- 4- {3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-
f]quinazolin-7-yl]-cyclopent-2-enyl}-piperazine-1-carboxylic acid *tert*-butyl ester;
- 2-(2,6-Dichlorophenylamino)-7-(3-hydroxycyclopent-1-enyl)-1-methyl-1,8-dihydro-9H-
5 imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-[3-(piperazine-1-sulfonyl)-phenyl]-1,8-dihydro-
9H-imidazo[4,5-f]quinazoline-9-one;
- 10 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-
f]quinazolin-7-yl]-cyclopent-3-enecarbonitrile;
- 7-Amino-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-
f]quinazoline-9-one;
- 15 3-{2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-
f]quinazolin-7-yl]-propenyl}-benzonitrile;
- 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-
20 f]quinazolin-7-yl]-cyclopent-3-enecarboxamide;
- 2-{4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H -imidazo[4,5-
f]quinazolin-7-yl]-thiazol-2-yl}-pyrrolidine-1-carboxylic acid benzyl ester;
- 25 2-(2,6-Dichlorophenylamino)-1-methyl-7-[1-methyl-2-(3-nitrophenyl)-vinyl]-1,8-dihydro-
9H-imidazo[4,5-f]quinazoline-9-one;
- 3-{4-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H -imidazo[4,5-
f]quinazolin-7-yl]-thiazol-2-ylmethyl}-piperidine-1-carboxylic acid benzyl ester;
- 30

- 7-[2-(2-Aminocyclohexyl)-thiazol-4-yl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-piperidin-3-ylmethyl-thiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-methylthiazol-4-yl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 2-(2,6-Dichlorophenylamino)-1-methyl-7-(3-oxocyclopent-1-enyl)-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-2,5-dihydro-pyrrole-1-carboxylic acid *tert*-butyl ester;
- 7-[2-(3-Aminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- Acetic acid 2-(4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-benzenesulfonyl}-piperazin-1-yl)-2-oxoethyl ester;
- 2-(2,6-Dichlorophenylamino)-7-(2,5-dihydro-1H-pyrrol-3-yl)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 7-[2-(3-Aminomethylphenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-dihydro-9H-imidazo[4,5-f]quinazoline-9-one;
- 4-{3-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9H-imidazo[4,5-f]quinazolin-7-yl]-benzenesulfonyl}-piperazine-1-carboxamide;

2-(2,6-Dichlorophenylamino)-7-{3-[4-(2-hydroxyacetyl)-piperazine-1-sulfonyl]-phenyl}-
1-methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

3-{2-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9*H*-imidazo[4,5-
5 *f*]quinazolin-7-yl]-propenyl}-benzamidine;

7-(7-Azabicyclo[2.2.1]hepta-2,5-dien-2-yl)-2-(2,6-dichlorophenylamino)-1-methyl-1,8-
dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

10 5-[2-(2,6-Dichlorophenylamino)-1-methyl-9-oxo-1,8,-dihydro-9*H*-imidazo[4,5-
f]quinazolin-7-yl]-3,3a,4,6a-tetrahydro-1*H*-cyclopenta[*c*]pyrrole-2-carboxylic acid *tert*-
butyl ester;

2-(2,6-Dichlorophenylamino)-7-(1,2,3,3a,4,6a-hexahydro-cyclopenta[*c*]pyrrol-5-yl)-1-
15 methyl-1,8-dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one;

2-(2,6-Dichlorophenylamino)-1-methyl-7-(2-pyrrolidin-2-yl-thiazol-4-yl)-1,8-dihydro-9*H*-
imidazo[4,5-*f*]quinazoline-9-one;

20 7-[2-(3,5-Diaminophenyl)-1-methylvinyl]-2-(2,6-dichlorophenylamino)-1-methyl-1,8-
dihydro-9*H*-imidazo[4,5-*f*]quinazoline-9-one; and

2-(2,6-Dichlorophenylamino)-1-methyl-7-[4-(piperazine-1-sulfonyl)-phenyl]-1,8-dihydro-
9*H*-imidazo[4,5-*f*]quinazoline-9-one;

25


and the pharmaceutically acceptable derivatives thereof.

12. A pharmaceutical composition comprising a therapeutically effective amount of a
30 compound according to claims 1, 6 or 10.

13. A method of treating an autoimmune disease, cancer or a cerebral ischemic condition said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claims 1, 6 or 10.
- 5 14. A method according to claim 13, wherein the autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, insulin-dependent diabetes mellitus and asthma.
- 10 15. A method according to claim 13, wherein the cancer is selected from a src-dependent tumor or a PDGF-dependent tumor.
16. A method according to claim 15, wherein the src-dependent tumor is selected from mammary carcinoma, colon carcinoma, melanoma and sarcoma.
- 15 17. A method according to claim 15, wherein the PDGF-dependent tumor is selected from ovarian cancer, prostate cancer and glioblastoma.
18. A method according to claim 13, wherein the cerebral ischemic condition is stroke.
- 20 19. A method of treating a disease selected from osteoporosis, Paget's disease, bone inflammation, and joint inflammation, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claims 1, 6 or 10.
- 25 20. A method of treating a disease selected from fibrotic diseases, restenosis and atherosclerosis, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claims 1, 6 or 10.
- 30

21. A method of enhancing or potentiating the effectiveness of radiation therapy by administering to a patient undergoing such therapy a therapeutically effective amount of compound according to claims 1, 6 or 10.

5 22. A compound of the following formula VI:



VI

wherein:

R is H, C₁₋₃alkyl or cyclopropyl;

10

R₄ is selected from H, C₁₋₆ alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with phenyl, OH or C₁₋₃alkoxy; or R₄ is selected from (CH₂)_mNR₈R₉, (CH₂)_mNR₈COR₁₀, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

15 R₈, R₉, R₁₀ and m are as defined in claim 1; and
n is 1-3;


wherein one or more of the primary amine or secondary amine nitrogen atoms in the R₄ substituent group may optionally be protected by a protecting group.

20

23. A compound according to claim 22, wherein R is H or C₁₋₃alkyl; R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉.

25

24. A compound of the following formula XII:



XII

wherein:

- R is H, C₁₋₃alkyl or cyclopropyl; and
R₅ is as defined in claim 1.

25. A compound according to claim 24, wherein:

- R is H or C₁₋₃alkyl;

R₅ is selected from H, C₁₋₃alkyl branched or unbranched, C₃₋₈ cycloalkyl, C₅₋₇cycloalkenyl or C₂₋₄ alkenyl, each being optionally substituted with one or more OH, CN, NR₈R₉, CONR₈R₉, C₃₋₈ cycloalkyl, C₅₋₇cycloalkenyl, phenyl, heteroaryl or heterocycle; wherein each phenyl, heteroaryl or heterocycle is optionally substituted with one or more C₁₋₃alkyl, C₁₋₃alkoxy, halogen, CN, NO₂, amidino, guanidino, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with C₁₋₃alkyl, phenyl, C₀₋₃alkyl, C₁₋₃alkoxy or CO₂R₁₀;

or R_5 is selected from CO_2R_{10} , NR_8R_9 , CONR_8R_9 , phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl, or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyridinyl, benzofuranyl, benzimidazolyl, 1,2,5,6-tetrahydro-pyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl, benzoyl or indolyl-CO- is optionally substituted with one to three:

halogen, NO_2 , $\text{S(O)}_p\text{NR}_8\text{R}_9$, $\text{C}_{0-3}\text{alkylS(O)}_p$, NR_8R_9 , $(\text{CH}_2)_n\text{CO}_2\text{R}_{10}$, ureido, guanidino, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, phenyl-Z-, heteroaryl-Z-, heterocycle-Z-, or $\text{C}_{1-3}\text{alkyl}$ optionally substituted with phenyl or NR_8R_9 , wherein Z is a bridging group selected from C_{1-3} alkylene branched or unbranched, O, S(O)_p or NH, and wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO_2 , $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, CO_2R_{10} , $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, phenyl $\text{C}_{0-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxy}$; and wherein each alkyl, alkoxy and phenyl in this paragraph is optionally partially or fully halogenated;

or R_5 is a C_{6-7} bridged-bicyclic ring system, optionally having one or two double bonds in the ring system, and wherein up to 1 carbon atom in the ring system may be replaced by a nitrogen atom; and wherein said ring system may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, halogen, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; 25 A compound according to claim 24, wherein:

25

R_5 is selected from C_{2-4} alkenyl, C_{3-8} cycloalkyl or C_{5-7} cycloalkenyl, each being optionally substituted with one or more OH, CN, NR_8R_9 , CONR_8R_9 or phenyl; wherein phenyl is optionally substituted with one or more $\text{C}_{1-3}\text{alkyl}$, $\text{C}_{1-3}\text{alkoxy}$, halogen, amidino, guanidino, $(\text{CH}_2)_n\text{NR}_8\text{R}_9$, or $\text{O}(\text{CH}_2)_{2-4}\text{NR}_8\text{R}_9$; wherein one or more of the amino nitrogens in the amidino or guanidino groups in this paragraph may be optionally substituted with $\text{C}_{1-3}\text{alkyl}$, phenyl $\text{C}_{0-3}\text{alkyl}$ or $\text{C}_{1-3}\text{alkoxy}$;


30

or R₅ is selected from phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO-, wherein each phenyl, furyl, thienyl, oxazolyl, thiazolyl, pyridinyl, benzofuranyl, 1,2,5,6-tetrahydropyridinyl, pyrrolinyl, 1,2,3,3a,4,6a-hexahydro-cyclopenta[c]pyrrolyl or indolyl-CO- is optionally substituted with one to two:

halogen, NO₂, SO₂NR₈R₉, NR₈R₉, (CH₂)_nCO₂R₁₀, ureido, cycloalkyl, phenyl, heteroaryl, heterocycle, cycloalkyl-Z-, heteroaryl-Z- or heterocycle-Z-, or C₁₋₃alkyl optionally substituted with NR₈R₉, wherein Z is a bridging group selected from C₁₋₃alkylene branched or unbranched or S(O)_p, wherein each cycloalkyl, phenyl, heteroaryl or heterocycle is optionally substituted with NO₂, C₁₋₃alkyl, CO₂R₁₀, NR₈R₉ or guanidino, wherein one or more of the amino nitrogens in the guanidino group in this paragraph may be optionally substituted with C₁₋₃alkyl; and wherein each alkyl and phenyl in this paragraph is optionally partially or fully halogenated;


or R₅ is a 7-azabicyclo[2.2.1]heptane ring system, optionally having one or two double bonds in the ring system, wherein said ring system may be optionally substituted with C₁₋₃alkyl, C₁₋₃alkoxy, halogen, (CH₂)_nNR₈R₉, or O(CH₂)₂₋₄NR₈R₉.

26. A method of making a compound of the formula Ib below:




wherein R is H, C₁₋₃alkyl or cyclopropyl, and Ar₁ and R₅ are as defined in claim 1, said method comprising:


- (a) reacting the compound of formula XIX (wherein R_4 is H) with an acid halide of the formula $R_5\text{COX}$, wherein X is a halogen, or with an acid anhydride of the formula $(R_5\text{CO})_2\text{O}$, or with an acid of the formula $R_5\text{CO}_2\text{H}$ and a coupling reagent, in a suitable solvent in the presence of a suitable base to form a compound of formula XXI:



- (b) cyclizing the compound of formula XXI by treatment with a suitable base in a suitable solvent at about reflux temperature to form a compound of formula Ib:




27. A method of making a compound of the formula Ib below:




wherein R is H, C₁₋₃alkyl or cyclopropyl, and Ar₁ and R₅ are as defined in claim 1, said method comprising:

- (a) reacting the compound of formula XIX (wherein R₄ is H) with an aldehyde of the formula R₅CHO in the presence of an acid in a suitable solvent to form a compound of formula Id:




; and

- (b) oxidizing the compound of formula Id with a suitable oxidizing agent to form the compound of formula Ib:



28. A method of making a compound of the formula Ib below:




wherein R is H, C₁₋₃alkyl or cyclopropyl, and Ar₁ and R₅ are as defined in claim 1, said method comprising:

5


- (a) reacting the compound of formula XVIII (wherein R₄ is H) with an acid halide of the formula R₅COX, wherein X is a halogen, or with an acid anhydride of the formula (R₅CO)₂O, or with an acid of the formula R₅CO₂H and a coupling reagent, in a suitable solvent in the presence of a suitable base to form a compound of formula XX:

10




15

- (b) hydrolyzing and cyclizing the compound of formula XX by treatment with a suitable base and a suitable oxidant in a suitable solvent to form the compound of formula Ib:



29. A compound of the following formula XVIII:



wherein:

Ar₁ is as defined in claim 1;

R is H, C₁₋₃alkyl or cyclopropyl; and

R₄ is as defined in claim 1.

30. A compound according to claim 29, wherein:

Ar₁ is

a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;

b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;

c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl,

d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl,

- benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazoliny, and indazolyl, or a fused heteroaryl selected from cyclopentenopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, 5 cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and 10 cyclohexanothiophene; or
- e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;
- 15 wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;
- R₁ and R₂ are as defined in claim 1, and R₃ is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and
- 20 R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;
- R₈ and R₉ are the same or different and are each independently selected from H, OH, C₁₋₃alkyl branched or unbranched, CO₂R₁₀, C₃₋₈cycloalkyl, phenyl, benzyl, benzoyl, 25 heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C₁₋₃alkoxy, C₁₋₃acyloxy, CO₂R₁₀, NR₁₁R₁₂, O(CH₂)₂₋₄NR₁₁R₁₂, aryl or heteroaryl;
- or R₈ and R₉ together form a 4-6 member alkylene chain completing a ring about the N 30 atom to which they are attached; wherein said alkylene chain is optionally interrupted by

NCO₂R₁₀ or NR₁₁; and wherein said ring is optionally substituted by C₁₋₃ alkyl,
C₁₋₃alkoxy, OH or -(CH₂)_nNR₁₁R₁₂;

R₁₀ is H or C₁₋₆alkyl optionally substituted with phenyl, OH, C₁₋₃alkoxy or NR₁₁R₁₂;

5

R₁₁ and R₁₂ are each independently selected from H and C₁₋₆ alkyl optionally substituted
with C₁₋₃alkoxy, OH or phenyl;

or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or
10 (CH₂)₂O(CH₂)₂; and

n is 0-3.

31. A compound according to claim 30, wherein:

15

Ar₁ is phenyl or pyridyl, each optionally substituted by one or more R₁, R₂ and R₃;

R is H or C₁₋₃alkyl;

20

R₁ and R₂ are the same or different and selected from: halogen, C₁₋₃ alkyl, wherein
the C₁₋₃ alkyl is optionally partially or fully halogenated, NO₂ or NR₈R₉;

R₃ is H, halogen, methyl or methoxy;

25

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally
substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉ or CO₂R₁₀;

R₈ and R₉ are the same or different and are each independently selected from H,
30 C₁₋₃alkyl branched or unbranched, CO₂R₁₀, phenyl, or benzoyl; wherein said alkyl, phenyl
or benzoyl are optionally substituted with OH or C₁₋₃alkoxy;

or R_8 and R_9 together form a $-(CH_2)_2-N(CO_2R_{10})-(CH_2)_2-$ group or a $-(CH_2)_2-N(R_{11})-(CH_2)_2-$ group; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, or OH;

5


R_{10} is H or C_{1-3} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy or $NR_{11}R_{12}$;

R_{11} and R_{12} are each independently selected from H and C_{1-3} alkyl optionally substituted with C_{1-3} alkoxy or OH;

10

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$.

15 32. A compound of the following formula XIX:



XIX

wherein:

- 20 Ar_1 is as defined in claim 1;
 R is H, C_{1-3} alkyl or cyclopropyl; and
 R_4 is as defined in claim 1.

33. A compound according to claim 32, wherein:

25

Ar₁ is

- a) a cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentanyl, cyclohexanyl and cycloheptanyl;
- b) a cycloalkenyl group selected from cyclopentenyl, cyclohexenyl, and cycloheptenyl;
- c) an aromatic carbocycle selected from phenyl, naphthyl, indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl or fluorenyl,
- d) a heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, thienyl, furyl, isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, benzpyrazolyl, benzothiofuranyl, benzothiazolyl, quinazolinyl, and indazolyl, or a fused heteroaryl selected from cyclopentanopyridine, cyclohexanopyridine, cyclopentanopyrimidine, cyclohexanopyrimidine, cyclopentanopyrazine, cyclohexanopyrazine, cyclopentanopyridazine, cyclohexanopyridazine, cyclopentanoquinoline, cyclohexanoquinoline, cyclopentanoisoquinoline, cyclohexanoisoquinoline, cyclopentanoindole, cyclohexanoindole, cyclopentanobenzimidazole, cyclohexanobenzimidazole, cyclopentanobenzoxazole, cyclohexanobenzoxazole, cyclopentanoimidazole, cyclohexanoimidazole, cyclopentanothiophene and cyclohexanothiophene; or
- e) a heterocycle selected from: pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, piperazinyl and indolinyl;

wherein each of the above Ar₁ are optionally substituted by one or more R₁, R₂ and R₃;

R₁ and R₂ are as defined in claim 1, and R₃ is hydrogen, halogen, methyl, methoxy, hydroxymethyl or OH; and

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉, (CH₂)_nCO₂R₁₀ or (CH₂)_nCONR₈R₉;

R_8 and R_9 are the same or different and are each independently selected from H, OH, C_{1-3} alkyl branched or unbranched, CO_2R_{10} , C_{3-8} cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle; wherein said alkyl, cycloalkyl, phenyl, benzyl, benzoyl, heteroaryl or heterocycle are optionally substituted with OH, C_{1-3} alkoxy, C_{1-3} acyloxy, CO_2R_{10} , $NR_{11}R_{12}$, $O(CH_2)_{2-4}NR_{11}R_{12}$, aryl or heteroaryl;

or R_8 and R_9 together form a 4-6 member alkylene chain completing a ring about the N atom to which they are attached; wherein said alkylene chain is optionally interrupted by NCO_2R_{10} or NR_{11} ; and wherein said ring is optionally substituted by C_{1-3} alkyl, C_{1-3} alkoxy, OH or $-(CH_2)_nNR_{11}R_{12}$;

R_{10} is H or C_{1-6} alkyl optionally substituted with phenyl, OH, C_{1-3} alkoxy or $NR_{11}R_{12}$;

R_{11} and R_{12} are each independently selected from H and C_{1-6} alkyl optionally substituted with C_{1-3} alkoxy, OH or phenyl;

or R_{11} and R_{12} together form a chain completing a ring, said chain is $(CH_2)_{4-5}$ or $(CH_2)_2O(CH_2)_2$; and

n is 0-3.

34. A compound according to claim 33, wherein:

Ar_1 is phenyl or pyridyl, each optionally substituted by one or more R_1 , R_2 and R_3 ;

R is H or C_{1-3} alkyl;

R_1 and R_2 are the same or different and selected from: halogen, C_{1-3} alkyl, wherein the C_{1-3} alkyl is optionally partially or fully halogenated, NO_2 or NR_8R_9 ;

R₃ is H, halogen, methyl or methoxy;

R₄ is H, C₁₋₃alkyl branched or unbranched, saturated or unsaturated, and optionally substituted with OH; or R₄ is (CH₂)₂₋₃NR₈R₉ or CO₂R₁₀;

5 R₈ and R₉ are the same or different and are each independently selected from H, C₁₋₃alkyl branched or unbranched, CO₂R₁₀, phenyl, or benzoyl; wherein said alkyl, phenyl or benzoyl are optionally substituted with OH or C₁₋₃alkoxy;

10 or R₈ and R₉ together form a - (CH₂)₂-N(CO₂R₁₀)-(CH₂)₂- group or a - (CH₂)₂-N(R₁₁)-(CH₂)₂- group; and wherein said ring is optionally substituted by C₁₋₃ alkyl, C₁₋₃alkoxy, or OH;

R₁₀ is H or C₁₋₃alkyl optionally substituted with phenyl, OH, C₁₋₃alkoxy or NR₁₁R₁₂;

15

R₁₁ and R₁₂ are each independently selected from H and C₁₋₃ alkyl optionally substituted with C₁₋₃alkoxy or OH;

20 or R₁₁ and R₁₂ together form a chain completing a ring, said chain is (CH₂)₄₋₅ or (CH₂)₂O(CH₂)₂.

25

30

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/014319 A3

(51) International Patent Classification?: C07D 487/04,
A61K 31/505 // (C07D 487/04, 239:00, 235:00)

(21) International Application Number: PCT/US01/24390

(22) International Filing Date: 2 August 2001 (02.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/224,724 11 August 2000 (11.08.2000) US

(71) Applicant: BOEHRINGER INGELHEIM PHARMA-
CEUTICALS, INC. [US/US]; 900 Ridgebury Road, P. O.
Box 368, Ridgefield, CT 06877-0368 (US).

(72) Inventors: SNOW, Roger, John; 29 East Gate Road, Dan-
bury, CT 06811 (US). GAO, Donghong, A.; 52 Harri-
son's Trail, Hopewell Junction, NY 12533 (US). GOLD-
BERG, Daniel, R.; 31 Highland Avenue, Redding, CT
06896 (US). HAMMACH, Abdelhakim; 8 Rolf's Drive,
Danbury, CT 06810 (US). KUZMICH, Daniel; 4 Driftway
Road, Unit C1, Danbury, CT 06811 (US). MORWICK,
Tina, Marie; 114 Taylor Road, New Milford, CT 06776

(US). MOSS, Neil; 199 Barlow Mountain Road, Ridge-
field, CT 06877 (US). PROKOPOWICZ III, Anthony,
S.; 20 Sun Up Road, Stormville, NY 12582 (US). SELL-
IAH, Robert, D.; 250 Kennedy Drive, #407, Malden, MA
02148 (US). TAKAHASHI, Hidenori; 68 Ehmer Drive,
LaGrangeville, NY 12540 (US).

(74) Agents: RAYMOND, Robert, P. et al.; Boehringer In-
gelheim Corporation, 900 Ridgebury Road, P. O. Box 368,
Ridgefield, CT 06877-0368 (US).

(81) Designated States (*national*): CA, JP, MX.

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

Published:

— with international search report

(88) Date of publication of the international search report:
1 August 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/014319 A3

(54) Title: HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES

(57) Abstract: Disclosed are novel compounds of formula (I) (see formula I as described in specification) wherein Ar₁, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 01/24390

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/505 //(C07D487/04,239:00,235:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 24035 A (SQUIBB BRISTOL MYERS CO) 20 May 1999 (1999-05-20) cited in the application abstract; examples 11,12 ---	1-34
A	WO 98 28281 A (CELLTECH THERAPEUTICS LTD ;DAVIS JEREMY MARTIN (GB); DAVIS PETER D) 2 July 1998 (1998-07-02) cited in the application abstract; claims ---	1-34
A	EP 0 322 746 A (ORION YHTYMAE OY) 5 July 1989 (1989-07-05) cited in the application abstract; formula II --- -/--	1-34



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

15 February 2002

Date of mailing of the international search report

05/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frélon, D

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 01/24390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KUMAR, SHIV ET AL: "Possible anthelmintic agents: syntheses of various imidazoquinazolinone carbamates" retrieved from STN Database accession no. 97:38906 XP002190316 abstract & INDIAN J. CHEM., SECT. B (1981), 20B(12), 1068-71 , ---	1-34
A	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; AGARWAL, SHIV K. ET AL: "Segregation of activity profile in benzimidazoles: effect of spacers at 5(6)-position of methyl benzimidazole-2-carbamates" retrieved from STN Database accession no. 120:124172 XP002190317 abstract & Z. NATURFORSCH., C: BIOSCI. (1993), 48(11-12), 829-38 , ---	1-34
A	US 4 176 184 A (AUSTEL VOLKHARD ET AL) 27 November 1979 (1979-11-27) abstract -----	1-34

INTERNATIONAL SEARCH REPORT

In International
PCT/US 01/24390**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 13-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 01/24390

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9924035	A	20-05-1999	AU 1371999 A	31-05-1999
			BR 9814956 A	03-10-2000
			CN 1290165 T	04-04-2001
			EP 1037632 A1	27-09-2000
			HU 0102101 A2	28-11-2001
			JP 2001522800 T	20-11-2001
			NO 20002121 A	09-05-2000
			PL 340727 A1	26-02-2001
			TR 200001312 T2	21-09-2000
			WO 9924035 A1	20-05-1999
			ZA 9810219 A	22-06-2000
WO 9828281	A	02-07-1998	AU 5330698 A	17-07-1998
			EP 0946523 A1	06-10-1999
			WO 9828281 A1	02-07-1998
			JP 2001507349 T	05-06-2001
			US 6057329 A	02-05-2000
EP 0322746	A	05-07-1989	AT 138658 T	15-06-1996
			DE 3855327 D1	04-07-1996
			EP 0322746 A1	05-07-1989
			US 4963677 A	16-10-1990
US 4176184	A	27-11-1979	DE 2732906 A1	08-02-1979
			DE 2732951 A1	08-02-1979
			AT 363945 B	10-09-1981
			AT 178880 A	15-02-1981
			AT 363946 B	10-09-1981
			AT 178980 A	15-02-1981
			AT 366383 B	13-04-1982
			AT 498878 A	15-08-1981
			AU 519769 B2	24-12-1981
			AU 3821078 A	24-01-1980
			BE 869191 A1	22-01-1979
			BG 30021 A3	16-03-1981
			CA 1091232 A1	09-12-1980
			CH 642367 A5	13-04-1984
			CS 204032 B2	31-03-1981
			DD 137933 A5	03-10-1979
			DK 323378 A	22-01-1979
			ES 471254 A1	01-10-1979
			ES 476166 A1	01-06-1979
			ES 476167 A1	16-04-1979
			ES 476168 A1	16-05-1979
			FI 782011 A ,B,	22-01-1979
			FR 2398069 A1	16-02-1979
			GB 2002751 A ,B	28-02-1979
			GR 65025 A1	16-06-1980
			HK 20685 A	29-03-1985
			HU 181000 B	30-05-1983
			IL 55168 A	13-09-1981
			IT 1107653 B	25-11-1985
			JP 1347743 C	13-11-1986
			JP 54022400 A	20-02-1979
			JP 61012912 B	10-04-1986
			LU 80001 A1	06-09-1979
			MY 113885 A	31-12-1985
			NL 7807760 A	23-01-1979

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 01/24390

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4176184	A	NO 782498 A ,B,	23-01-1979
		NZ 187916 A	01-05-1981
		PH 15801 A	25-03-1983
		PL 208543 A1	21-05-1979
		PT 68329 A	01-08-1978
		SE 441746 B	04-11-1985
		SE 7808018 A	22-01-1979
		SG 185 G	14-06-1985
		SU 688129 A3	25-09-1979
		YU 174778 A1	28-02-1983
		AT 363947 B	10-09-1981
		AT 179080 A	15-02-1981
		IE 46963 B1	16-11-1983
		ZA 7804123 A	26-03-1980
